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ABSTRACT OF DISSERTATION
DAPK3 Suppresses Mammary Acini Morphogenesis and is Required for Mouse Development
by
Brandon Anthony Miller Kocher
Doctor of Philosophy in Biological and Biomedical Sciences
Molecular Cell Biology
Washington University in Saint Louis, 2014
Dr. David Piwnica-Worms, Chairperson

Over the past decade several lines of research have indicated that DAPK3, a member of the
serine/threonine death associated protein kinase (DAPK) family, plays an important role in
various signaling pathways important to tissue homeostasis and mammalian biology. Considered
to be a putative tumor suppressor, the molecular mechanisms by which DAPK3 exerts its tumor
suppressor functions are not fully understood. Furthermore, unlike other DAPK family members,
DAPK3 has received little attention regarding its physiological roles in vivo due to the lack of
knockout animals. To address these gaps in our fundamental understanding of DAPK3 we
utilized the MCF10A 3D tumorigenesis model in vitro and generated a constitutive DAPK3
knockout mouse. Using the MCF10A 3D morphogenesis model we identified that loss of
DAPK3 through lenti-viral mediated knockdown accelerates MCF10A acini proliferation and
apoptosis while maintaining acini polarity relative to negative control. Furthermore, depletion of
DAPK3 leads to enhanced growth factor–dependent mTOR activation and enlarged DAPK3
structures are uniquely sensitive to low doses of rapamycin treatment compared to negative
control. Simultaneous knockdown of RAPTOR (a key mTORC1 component) rescues the
viii

augmented acinar size in DAPK3 depleted structures indicating an epistatic interaction. To
identify the overall physiological contribution of DAPK3 we generated a constitutive DAPK3
knockout mouse using a gene trap embryonic stem cell line from the International Gene Trap
Consortium. Described herein we have identified that DAPK3 is vital for early mouse
development and that the Dapk3 promoter exhibits spatio-temporal activity in the developing
heart and nervous system in addition to the gastrointestinal myenteric plexus of adult mice.
Importantly, our data suggests that DAPK3 is expressed in the breast epithelia of adult mice and
that potential ablation of DAPK3 expression can facilitate the development of breast cancer as
observed in primary patient biopsies.

Our studies shed light on the growth inhibitory

mechanisms of DAPK3 and provide direct evidence that DAPK3 plays an underappreciated role
in mouse development, warranting further studies.

ix

CHAPTER 1: INTRODUCTION
1.1 Death-associated protein kinase family (DAPK)
The death-associated protein kinase (DAPK) family is a relatively novel group of serine/
threonine kinases characterized by shared kinase domain homology as well as a pronounced cell
death phenotypes upon overexpression. DAPK1, the prototypical family member, was first
identified as a positive regulator of interferon gamma-induced cell death in HeLa cells using an
anti-sense cDNA library screen (1). Additional studies indicated that the intrinsic cell death
promoting activities of DAPK1 were dependent on its kinase activity; a characteristic soon found
true for all DAPK family members (2). The DAPK family is phylogenetically related to the
CaM-regulated kinases and includes 5 members: DAPK1, DAPK2 (DRP1), DAPK3 (ZIPK),
DRAK1 (STK17A), and DRAK2 (STK17B) (Figure 1.1) (3).

In addition to the similar

overexpression phenotypes, the family is defined by amino acid sequence homology that exists
between each member’s N-terminal kinase domain. Despite similar kinase domains, family
members differ drastically through the presence of additional regulatory domains. DAPK1 has a
Ca2+/ CaM regulatory domain, ankyrin repeats, a cytoskeletal binding and death domain.
DAPK2 also contains a Ca2+/ CaM regulator domain but lacks these additional domains similar
to DAPK3, DRAK1 and 2. Overall, this family has diverse roles in inflammation, stressresponse, muscle contraction, tumor suppression and cell death.
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1.2 DAPK3
While DAPK1 has received the most attention regarding biochemical function and
phenotypes, relatively little is known about DAPK3. DAPK3 shares 83% amino acid homology
within its kinase domain but lacks the additionally regulatory domains observed in DAPK1.
DAPK3 also contains three putative C-terminal nuclear localization signals in addition to a
leucine zipper motif (Figure 1.1). DAPK3 was first identified as an ATF4 interaction partner
through a yeast two-hybrid screen using respective leucine zipper domains from a mouse cDNA
library (4). The leucine zipper domain of DAPK3 is also required for homodimerization.
Currently no clear regulation of DAPK3 endogenous activity has been determined. However,
upon overexpression, DAPK3 and DAPK1 interact via their kinase domains resulting in transphosphorylation of DAPK3 by DAPK1 at various sites. This DAPK1-DAPK3 signaling cascade
is required for the activation of a translational inhibitory gene expression program (5).
Functional DAPK3 studies are limited by the lack of a knockout mouse (constitutive or
conditional knockout).

One group reportedly attempted to generate a conditional DAPK3

knockout mouse but admitted its failure through personal communications (Hagerty L &
Haystead T. Unpublished Thesis Dissertation, 2007). Commonly used model systems such as
Caenorhabditis elegans, Saccharomyces cerevisiae, and Drosophila melanogaster lack clear
DAPK3 orthologues, thereby hindering traditional genetic interrogation.

Uncovering the

physiological contributions of DAPK3 is crucial to understanding the relevancy of previous
clinical and basic research observations. Furthermore, DAPK1 and DAPK3 inhibitors are
currently under development for use in smooth muscle related disorders and a DAPK3 deficient
2

animal may indicate potentially deleterious phenotypes associated with loss of a functional
DAPK3 protein (6,7).
Further hampering the functional understanding of DAPK3, many groups have published
conflicting reports concerning the localization and respective molecular functions of DAPK3.
One group of research indicates that ectopically expressed DAPK3 resides mainly within the
cytoplasm and induces membrane blebbing, cell rounding and actin filament assembly (8,9).
DAPK3 cytoplasmic subcellular localization has also been shown to correlate with its death
inducing function in certain animal cell lines (3). These phenotypes have been attributed to
DAPK3’s direct phosphorylation of myosin light chain II (MLC) (8) and/ or GTP-dependent
RhoD-mediated actin reorganization and actomyosin contraction (9). An additional cytoplasmic
function of DAPK3 involves Ca2+ sensitization and smooth muscle contraction that is dependent
on DAPK3 mediated phosphorylation of MLC and inactivation of smooth muscle myosin
phosphatase (SMMP-1M) and CPI17 (7,10).
Contrasting with these cytoplasmic observations, other groups have indicated a nuclear
specific localization and subsequent molecular action of DAPK3. Upon ectopic expression of
DAPK3 by other groups, DAPK3 was observed to display nuclear localization with a ‘speckled
pattern’ considered to be promyelocytic leukemia oncogenic bodies (PODs) (4,11–14).
Subsequent research indicated that DAPK3 participates in the translocation of pro-cell death
proteins DAXX (Fas death domain-associated protein) and PAR-4 (prostate apoptosis response4) to PODs (13,15,16).

3

These

discrepancies

regarding

DAPK3

subcellular

localization

and

resulting

overexpression phenotypes have recently been resolved. Through overexpression and sequence
alignment studies in various cell lines Shoval et al revealed that ectopically expressed human and
zebrafish DAPK3 resides in the cytoplasm while rat DAPK3 localizes specifically to the nucleus
(17). Indeed, the majority of DAPK3 nuclear localization studies were performed using rat
DAPK3 in established rat cell lines while cytoplasmic studies were performed using human
DAPK3 in human cell lines such as HEK293T and HeLa. These studies shed light on additional
questions regarding protein interaction partners. Rat DAPK3 was found to strongly interact with
PAR-4 while human and zebrafish do not bind PAR-4. The authors also hypothesized that mouse
DAPK3 is localized to the nucleus based upon amino acid sequence similarities but did not
report any actual localization studies. These studies have identified a phylogenetic specific
divergence for localization and potentially function of DAPK3 but questions still remain
regarding the localization-dependent function of mouse DAPK3.

1.3 DAPK3 & Cancer
Two clear lines of research regarding DAPK3 related phenotypes exist: cell death and
cytoskeletal regulation. From a fundamental cell biology perspective these cell death or ‘tumor
suppressive’ observations are mainly inferred through ectopic expression of DAPK3 and other
DAPK family members. Specifically, members of the DAPK family are considered to be
involved in ‘apoptotic’ and/ or autophagy-related cell death programs with varying degrees of
experimental support for each member. However, despite various reports regarding the role of
DAPK members in autophagy (via LC3 punctate structures or processing) no additional
4

autophagy –rescue experiments (chemical or genetic) have been published that would satisfy the
official Nomenclature Committee on Cell Death of 2012 (18). Additionally, notable
discrepancies regarding their role in apoptosis exist, largely due to the old-world
misinterpretation of ‘apoptotic’ cells displaying ‘characteristic apoptotic’ morphology. These
‘apoptotic morphologies’ include membrane blebbing (commonly observed in dividing, mobile
and apoptotic cells) (19), loss of membrane integrity (20) and DNA condensation or
fragmentation (sub G1 content). Ectopic overexpression of DAPK1 or DAPK3 does not lead to
caspase-dependent apoptosis as seen by the lack of apoptotic caspase activation and PARP
cleavage, but DNA degradation has been observed (21–23). Collectively, these results suggest
that overexpression of DAPK1/ DAPK3 causes a form of cell death similar to caspaseindependent or necrotic cell death as cells detach and lose membrane integrity. Since the
majority of exploratory DAPK-mediated cell death experiments have occurred in the context of
ectopic overexpression, it is possible that the observed cell death is secondary to cell detachment
due to forced cytoskeletal contraction and rearrangement. Indeed, it is well known that various
members of the DAPK family participate in cytoskeletal dynamics through phosphorylation and
direct interaction with MLC, ROCK1, RhoD, MLCK, and CPI-17 (3). However, notable
biochemical features of anoikis as determined by the Nomenclature Committee on Cell Death of
2012, such as caspase activation, are not observed in ectopic expression experiments. While the
type of cell death observed upon ectopic expression of DAPK3 remains to be determined, several
clinical observations suggest these growth inhibitory properties are inactivated in various
cancers.

5

Alterations within the DAPK3 coding sequence and its expression have been observed in
several types of cancers prompting investigation into the tumor suppressive mechanisms of
DAPK3.

Heterozygous loss-of-function mutations were identified in various cancers that

influenced cell survival, proliferation, aggregation and chemotherapy resistance (23).
Additionally, reduced DAPK3 mRNA expression correlated with tumor invasion, metastasis and
was a poor prognostic factor in a population of over 160 gastric cancer patients (24).

These

observations are not specific to gastric cancer as knockdown of DAPK3 increases proliferation
of various malignant cell lines in vitro (23). Abrogation of DAPK3 mRNA expression was
shown to significantly decrease cisplatin sensitivity in lung cancer cell lines and its
downregulation may impact overall survival of non-small cell lung cancer patients treated with
platinum-based therapy (25). DAPK3 is also considered a potentially novel breast cancer gene
as recurrent DAPK3 alterations were observed in BRCA1 mutant and BRCA-1 non-mutant
breast cancers (26). Additionally, DAPK3 has been shown to interact with and/ or phosphorylate
various proteins in vitro that are involved in cancer including ATF4, AATF, Daxx, Par-4,
STAT3, NLK, and AR (4,14,27–32). These basic research and clinical observations have spurred
further interest into defining the key molecular pathways regulated by DAPK3 in the hopes of
identifying novel anti-cancer therapies.
These observations are not unique to DAPK3 and are similarly observed for DAPK1, the
most well characterized tumor suppressor of the DAPK family. Originally identified as a
potential mediator of interferon gamma -induced cell death, DAPK1 has since been regarded as a
bona fide tumor suppressor in large part through the efforts of the Dr. Adi Kimchi Lab (1). It was
first posited that DAPK1 is a tumor suppressor after identification of non-existent DAPK1
6

protein expression in various human cancer cell lines that could be partially restored by DNA
demethylation (33). Since these initial studies it has been shown that DAPK1 ectopic expression
can reduce metastasis and soft agar colony formation (34). Others have shown that DAPK1
overexpression activates p19ARF/p53 dependent ‘apoptosis’ in a kinase-dependent manner and
that DAPK1 is required for p53 induction following oncogene activation (via overexpression of
c-Myc and E2F-1) (35). Another group showed that DAPK1 mRNA expression is induced upon
DNA damage in a p53-dependent manner (36). Indeed, it appears that DAPK1 is mainly
regulated through epigenetic repression of DAPK1 mRNA expression via promoter
hypermethylation. The DAPK1 promoter is hypermethylated in various cancers including lung,
bladder, head and neck, kidney, breast and B cell malignancies relative to normal tissues (37–
42). Interestingly, despite these hypermethylation observations, several studies have shown that
DAPK1 protein remains largely unaffected in certain patient cohorts (42). Given that no loss-offunction mutations have been reported for DAPK1, research performed to date indicates mRNA
expression as a crucial means of regulating DAPK1 and potentially other DAPK members such
as DAPK3.

1.4 The mTOR Pathway
My research has identified DAPK3 mediated inhibition of the mTOR pathway as a novel
growth inhibitory or tumor suppressive mechanism and further discussion requires an
introduction to the mTOR pathway.
The ‘mechanistic target of rapamycin’ or mTOR protein kinase was initially identified as
a crucial mediator of the profound anti-proliferative effects exerted by rapamycin, a macrolide
7

produced by Streptomyces hygroscopicus. mTOR was first purified and determined to be a
functional target of rapamycin in the early 1990s (43–45). Since its initial discovery the mTOR
pathway has been implicated as a major regulator of cellular and tissue energy metabolism,
growth and proliferation (46). As a member of the phosphoinositide 3-kinase (PI3K)-related
kinase family, mTOR is considered to be an atypical serine/ threonine non-lipid protein kinase.
mTOR interacts with a variety of protein binding partners and ultimately forms two distinct and
massive protein complexes (mTORC1 and mTORC2) that respond to and regulate a diverse
array of upstream and downstream signaling (Figure 1.2). Both complexes respond to a variety
of stimuli and regulate a number of key processes including cell growth, metabolism autophagy
and many other biologic programs.
The large mTORC1 and mTORC2 complexes are composed of a unique set of interaction
partners that help regulate the diversity of functions controlled by the mTOR pathways.
mTORC1 is comprised of six known subunits including the catalytic mTOR subunit, mammalian
lethal with sec-12 protein 9 (mLST8/ GβL) (47), DEP domain containing mTOR-interacting
protein (DEPTOR) (48), the scaffold protein complex Tti1/Tel2 (31), regulatory-associated
protein of mammalian target of rapamycin (raptor) (49,50), and proline-rich Akt substrate 40
kDa (PRAS40) (51–54). Similarly, the relatively rapamycin insensitive mTORC2 shares mTOR,
mLST8 (55), DEPTOR (48) and Tti1/ Tel2 (31) but differs through interactions with rapamycininsensitive companion of mTOR (rictor) (55,56), mammalian stress-activated map kinaseinteracting protein 1 (mSin1) (57,58) and protein observed with rictor 1 and 2 (protor1/2)
(52,59,60). Rapamycin directly inhibits mTOR when it is associated with mTORC1 through
allosteric kinase inhibition (61–63) and/ or structural disruption (49,64).
8

mTORC1 is the most well understood of the two mTOR complexes and it responds to a
diversity of signals including growth factors, stress, energy status, oxygen and amino acids.
Using the epidermal growth factor (EGF) pathway as a representative example, mTORC1 is
activated by two major signaling pathways downstream of the EGF receptor (EGFR): PI3K-AKT
and RAS-ERK (65). Extracellular binding of EGF to the receptor tyrosine kinase EGFR induces
receptor homo- and/or heterodimerization of EGFR monomers resulting in cytoplasmic transand/ or autophosphorylation and subsequent activation of PI3K-AKT and RAS-ERK pathways.
The initial stages of activation for both pathways involve proximity-based activation through
phosphatidylinositol-phosphoinositide dependent kinase 1 (PDPK1) (66) and growth factor
receptor-bound protein 2 (GRB2) -son of sevenless (SOS) for AKT and RAS-ERK, respectively
(67). The effector components of both pathways ultimately converge on phosphorylation and
inhibition of the tuberous sclerosis complex (TSC) which is made up of TSC1, TSC2 and Tre2Bub2-Cdc16 (TBC) 1 domain family member 7 (TBC1D7). This effectively activates mTORC1
through an as of yet not well understood mechanism (68).
Once activated, downstream components of mTORC1 signaling regulate cell growth (cell
mass), macromolecular biosynthesis, autophagy, and cell cycle progression.

mTORC1

regulation of protein synthesis is the most fundamental and well understood mechanism by
which mTORC1 influences these multiple cell processes. Once activated, mTORC1 directly
phosphorylates two key protein translational and synthesis regulators: eukaryotic initiation factor
4E-binding protein 1 (4E-BP1) and S6 kinase (S6K) (69). Overall, regulation of these
components ultimately controls translation of key transcripts involved in ribosome biogenesis,
cell cycle, anti-apoptosis, metastasis, angiogenesis and glycolysis. mTORC1 mediated
9

phosphorylation of 4E-BP1 prevents it from inhibiting the assembly of eIF4E at the 5’ mRNA
cap thereby effectively facilitating the formation of the pre-initiation complex at the ribosome.
mTORC1 initiates S6K activation through phosphorylation of T389 which creates a docking site
for PDPK1 allowing it to phosphorylate S6K at T229 (69). Once activated by mTORC1, S6K
phosphorylates a variety of translational regulator substrates including eukaryotic elongation
factor 2 kinase (eEF2K), S6 Aly/ REF-like target (SKAR) and ribosomal protein S6 (S6) which
ultimately facilitates translation initiation and elongation (70). An increase in the translation of
cell cycle progression, ribosomal protein and translational elongation factor mRNA transcripts
correlates with the phosphorylation of S6 (71). Interestingly, primary mouse embryonic
fibroblasts (MEFs) produced from mice with homozygous knock-in S->A mutations at key S6
phosphorylation sites, display decreased cell size but augmented protein synthesis and cell
division (72). Moreover, MEFs produced from mice devoid of all three 4E-BPs (1-3) display
increased proliferation (73). While these observations suggest S6 positively regulates cell growth
and 4E-BPs negatively regulate proliferation, it is generally accepted that phosphorylation of 4EBP1 and S6K-S6 serve as representative mTORC1 specific markers. And, that these markers are
indicative of other mTORC1 specific translational programs that might be directly involved in
the regulation of proliferation and cell growth, independent of these markers.

Indeed, it is

anticipated that phospho-S6 and phospho-4E-BP1 will serve as pharmacodynamic markers for
mTORC1 activity in oncology clinical trials (74).
While much is known about mTORC1, only a handful of studies in the past 10 years have
shed light on the mTORC2 pathway. mTORC2 integrates signals mainly from growth factors to
control cell metabolism, cytoskeletal organization and cell survival. mTORC2 activates several
10

members of the AGC subfamily of kinases (AKT, and SGK1 or serum-and glucocorticoidinduced protein kinase 1) thereby regulating the phosphorylation of forkhead box O1/3a
(FoxO1/3a) and the subsequent transcription of genes required for metabolism, cell cycle arrest
and apoptosis (75,76). mTORC2 also activates protein kinase C-α (PKC-α) thereby playing a
pivotal role in cell shape and actin cytoskeleton dynamics (55,56).

1.5 mTOR & Cancer
Pre-clinical and clinical observations indicate that mTORC1 and 2 are crucial for the
development of cancer and as such have become attractive anti-cancer targets. Activating
mutations in PI3K or deletion of the PI3K inhibitory protein, phosphatase and tensin homologue
(PTEN), are commonly observed in human cancer resulting in hyperactivation of mTOR and
AKT (77). Several negative regulators of the mTOR pathway are bona fide tumor suppressors
and are widely deregulated in various human cancers. Inherited mutations in TSC1 and 2 causes
tuberous sclerosis, a familial cancer that results in hamartomas and benign tumors in various
organs (78). Conditional loss of TSC1 in the liver of mice results in hyperactive mTORC1
signaling and hepatocellular carcinoma, the development of which recapitulates human liver
carcinogenesis (79). Another familial cancer syndrome, Peutz Jegher’s syndrome, is caused by
the loss of the tumor suppressor liver kinase B1 (LKB1) which results in the development of
intestinal polyps and dramatically increases a patients risk for other cancers (80). LKB1 is
deleted in 58% of lung cancers and is known to be a major negative regulator of mTORC1
signaling through AMPK mediated activation of the TSC complex (81).

11

Given these profound clinical oncology observations, mTOR inhibition has become a key
therapeutic focus for anti-cancer therapies including combination therapy. This is supported by
two recent studies that determined several tumors develop resistance to PI3K and BRAF
inhibitors through mTORC1 signaling (82,83). Over the past decade rapamycin and several nextgeneration mTORC-specific inhibitors (rapalogues and mTOR kinase inhibitors) have witnessed
improved clinical safety profiles but limited clinical efficacy (74).

These targeted therapies

have failed due to activation of compensatory mechanisms and partial inhibition of the
mTORC2-AKT pathway (74). Interestingly, out of 750 human cancer samples only 3 mTOR
activating mutations with functional significance have been identified (84). Indeed, many
regulators of the mTORC1 pathway that promote growth factor-independent activation of
mTORC1 are upregulated in 80% of human cancers (85). Collectively, this indicates that
alternative strategies to effectively inhibiting the mTOR pathway are required
While many of the major regulators of the mTOR pathway have been elucidated, new
regulators are continually being identified which will undoubtedly shed light on the complexities
of the mTOR pathway, its many negative feedback loops and potentially new anti-cancer
therapeutic targets. Taking a different approach, we hypothesize that rather than therapeutically
inhibiting mTOR, an alternative strategy might include supporting the negative regulation of
intrinsic mTOR-suppressive pathways.

1.6 DAPK and mTOR Pathway Interactions
As discussed above, the mTOR pathway is a critical regulator of various pathways found
to be influenced by the DAPK family including proliferation, ‘autophagy’, survival, cell death
12

and cell cycle regulation. Interestingly, several members of the DAPK tumor suppressor family
are known to regulate translation and regulate or be regulated by the mTOR pathway. Recent
work has uncovered conflicting roles with regards to DAPK1-mediated regulation of the mTOR
pathway. One group revealed that DAPK1 positively regulates mTOR activity through disruption
of TSC1-TSC2 interactions (86). Another group revealed that DAPK1 negatively regulates
protein translation through an inhibitory phosphorylation at S235/236 of S6 (87). However,
research by Roux et al. revealed that phosphorylation of S235/236 on S6 by RSK actually
promotes translation through enhanced assembly of the translational pre-initiation complex (88).
DRAK2 was shown to phosphorylate S6K in vitro and play a functionally significant role in islet
cell apoptosis (89). Overall, while some precedent exists, more work is required to identify and
understand the functional connections between the DAPK family and mTOR regulation.

1.7 Three-Dimensional Cell Culture as a Powerful Model of Breast
Cancer for Elucidating Novel DAPK3 Functions
It is clear that further research regarding the tumor suppressive functions of DAPK3 is
warranted. Specifically, little is known about the functional tumor suppressive mechanisms
regulated by DAPK3. Research on DAPK3 is further hampered by the lack of reliable
immunohistochemical and immunofluorescence antibodies that can specifically recognize
endogenous levels of mouse or human DAPK3 protein. These limitations are exacerbated by the
lack of a knockout mouse model as well as inadequate cell culture models that cannot
recapitulate the physiological context of tissue development or carcinogenesis.
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Given these setbacks we have utilized a well-established three-dimensional (3D) in vitro
epithelial tumor system that has been extensively used by other groups to study tumor
suppressors and oncogenes. Studying tumor suppressors, such as DAPK3, in two-dimensional
(2D) cell culture omits many of the complex external factors that are crucial to tissue
homeostasis and carcinogenesis. Culturing cancer cells in or on an extracellular matrix (ECM)
such as Matrigel (a protein mixture collected from Engelbreth-Holm-Swarm mouse sarcoma
cells) or collagen supports the development of cell spheroids that closely resemble the
architecture of glandular epithelial structures (90). 3D epithelial tumor structures form through
coordinated series of biochemically-regulated events that are commonly deregulated in cancer
including polarization, proliferation, survival, invasion, and apoptosis (Figure 1.3 A). Examining
the relative contribution of tumor suppressor and oncogenes to the morphogenic phenotypes
observed in 3D tumor systems serves as an accurate and approachable model for studying
histopathological idiosyncrasies observed in human epithelial cancers in vivo. Furthermore, each
structure represents a simplified tumor that can be studied and quantified in a relatively high
throughput manner. Given the financial constraints of the current scientific research budget, the
variability and still costly mouse models of cancer, 3D in vitro tumor systems are a highly
attractive model for current basic cancer research.
One of the most well characterized 3D epithelial tumor systems utilizes the nontransformed, immortalized breast epithelial MCF10A cell line. When seeded as a single cell
suspension atop solidified Matrigel, MCF10A cells eventually develop in to hollow acinar
structures that cease to proliferate after 2 weeks (Figure 1.3 A). These structures undergo a
coordinated series of biochemical and phenotypic processes and mimic true mammary acini
14

development. Early in the development of these hollow acini apical-basolateral cell polarity is
established. After 5-6 days a population of cells loses contact with the ECM and eventually
undergoes apoptosis. Cells that maintain contact with the ECM exhibit survival signaling
through AKT and continue to proliferate. As the internal cells overcome pro-survival autophagy,
they begin to undergo apoptosis and form a hollow lumen that closely resembles the glandular
architecture seen in the human breast (91,92). This system allows dissection of the biochemical
pathways and the respective functional contributions of novel regulatory proteins to the wellestablished 3D phenotypes of commonly deregulated oncogenic and tumor suppressive
pathways. Indeed, the phenotypes of many cancer-associated genes have been characterized in
detail, including HPV16 E7, ERBB2, AKT , CSF, LKB1, c-Myc, p38, PI3K, ERK1/2, Notch,
STAT3, NF-κB and importantly mTORC1 (90,93–100) (Figure 1.3 B).
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1.8 Figures

Figure 1.1 mTOR pathway and its contribution to tumorigenesis. Image amended from
Laplante, M, & Sabatini, D. 2012 (46).
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DAPK1

DAPK2

DAPK3

DRAK-1

DRAK-2

Figure 1.2 Schematic representation of the death associated protein kinase family (DAPK).
Various regulatory domains are highlighted in addition to the amino acid homology relative to
DAPK1. Image amended from Bialik, S. & Kimchi A. 2006 (3).
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A

B

Figure 1.3 MCF10A morphogenesis (A) Schematic representation of the timeline of MCF10A
acini development when grown on Matrigel. Apical-basolateral polarity is initiated by days 4 -6
(Lamini5 and GM130). Two clear populations of cells, proliferative and apoptotic, start to
emerge at days 6-8. Cells that have lost contact with the Matrigel undergo apoptosis/ anoikis
while the peripheral cells display increased AKT signaling. Eventually these structures cease to
proliferate at day ~15 forming hollow structures. (B) The well characterized contribution of
oncogenes to MCF10A morphogenesis.
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CHAPTER 2: DAPK3 INHIBITION OF mTOR SIGNALING
SUPPRESSES MAMMARY ACINI MORPHOGENESIS
2.1 Introduction
Death-associated protein kinase 3 (DAPK3, also known as ZIPK) is a member of the
DAPK serine/ threonine protein kinase family and is known to regulate smooth muscle
contraction, cell-cell adhesion, cytoskeleton dynamics, inflammation,

and cardiovascular

functions. It is also considered a putative tumor suppressor through regulation of caspasedependent and -independent apoptosis, proliferation and autophagy (1). The DAPK family
contains 4 other members, including DAPK1, DRP-1 (DAPK-related protein 1), DRAK-1 and
DRAK-2 (DAPK-related apoptosis-inducing protein kinase-1 and -2), which all share homology
within their kinase domain. DAPK3 contains an N-terminal kinase domain that shares 80%
amino acid homology with the prototypical DAPK1. It differs from other family members by the
presence of a C-terminal leucine zipper motif and the absence of a calmodulin-regulated (CaM)
domain and death domain. Similar to other family members, DAPK3 is considered to be a tumor
suppressor. Overexpression of DAPK3 in mammalian cells results in cell death and cell cycle
inhibition while kinase inactivating mutations along with recurrent deleterious somatic mutations
are observed in lung and breast cancers, respectively (2-4). Knockdown of DAPK3 increases
proliferation of various cell lines (2).

Clinically, reduced DAPK3 mRNA correlated with

increased tumor invasion, metastasis and overall survival in a cohort of gastric carcinoma
patients (5). Abrogation of DAPK3 mRNA expression was shown to significantly decrease
cisplatin sensitivity in various lung cancer cell lines and may impact overall survival of nonsmall cell lung cancer patients treated with platinum-based therapy (6). DAPK3 is also
considered a potentially novel breast cancer gene as recurrent DAPK3 alterations were observed
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in BRCA1 mutant and BRCA-1 non-mutant breast cancers (3). Additionally, human DAPK3
regulates a variety of signaling pathways commonly deregulated in cancer. For example, DAPK3
negatively regulates the canonical Wnt/ β-catenin pathway by disrupting the interaction between
Nemo-like kinase (NLK) and T-cell Factor 4 (TCF4) in colon cancer cell lines (7). DAPK3
regulates androgen receptor-mediated transcription via ubiquitination and degradation of AR in
various cancer cell lines (8). DAPK3 also interacts with and/ or phosphorylated various cancerassociated proteins in vitro, including ATF4, AATF, Daxx, Par-4 and STAT-3 (4,9-12).
Despite these in vitro and clinical observations, the full physiological significance of
DAPK3 is not well understood. Compared to the prototypical DAPK family member DAPK1,
relatively little is known about the functional tumor suppressive mechanisms regulated by
DAPK3. These limitations are potentially exacerbated by the lack of a knockout mouse model as
well as inadequate cell culture models that cannot recapitulate the physiological context of tissue
development or carcinogenesis.
3-dimensional (3D) in vitro tumor systems provide the ability to functionally investigate
the contribution of tumor suppressors and oncogenes to the complex development and
architecture of tumor spheroids (13). Given the utility of 3D tumor systems and the clinically
observed mutations of DAPK3 in breast cancer (3), we chose to further explore the functional
significance of DAPK3 in a MCF10A 3D morphogenesis model.

When grown on an

extracellular enriched matrix (Matrigel), the immortalized MCF10A epithelial cell line forms
hollow spheroids that undergo a regulated and coordinated series of events similar to developing
mammary acini (14). This model has been used to investigate the contribution of loss-offunction (LOF) alterations to acini development and early events in tumor formation.
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Herein, we describe the functional significance of DAPK3 in MCF10A acini
morphogenesis. We have identified that DAPK3 negatively regulates MCF10A morphogenesis
through a mTORC1-S6K1-S6 pathway. We also identified that DAPK3 is downregulated in
aggressive breast cancer relative to less aggressive and normal patient samples.

2.2 Materials & Methods
Cell culture and reagents
MCF10A and 293T cells were obtained from the American Type Culture Collection. MCF10A
cells were cultured as described elsewhere (14) and 293T were cultured in DMEM supplemented
with 10%FBS and L-glutamine. 3D morphogenesis assays were conducted as described
elsewhere (14).

Plasmids and viral production
For DAPK3 overexpression, the DAPK3 ORF was PCR amplified (from Addgene plasmid
23436) and subcloned into pLVX-IRES-Hyg (Clonetech). PCR primers, forward: 5’GAGAGACTCGAGGCCACCATGTCCACGTTCAGGCAGGAG,

and

reverse:

5’-

GAGAGAGGATCCTTACTAGCGCAGCCCGCACTCCACGCCCTGC, were used to create
the restriction enzyme sites XhoI and BamHI (in bold) that allowed for ligation into the
corresponding sites in pLVX-IRES-Hyg. For HRasV12 overexpression, HRasV12 was amplified
and

subcloned

into

pLVX-IRES-Hyg.

PCR

primers,

forward:

5’-

GAGAGACTCGAGGCCACCATGACGGAATATAAGCTGGTGGTGGTGG, and reverse: 5’GAGAGAGGATCCTTATCAGGAGAGCACACACTTGCAGCTCATG, were used to create
the restriction enzyme sites XhoI and BamHI (in bold) that allowed for ligation into the
corresponding sites in pLVX-IRES-Hyg.
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pLKO.1-puro constructs obtained from the Genome Institute at Washington University were
used for RNA interference (RNAi) against DAPK3. Sequences for the short hairpin RNAs are:
5’-

CGTTCACTACCTGCACTCTAA

(herein

referred

to

as

sh1),

5’-

CCCAAGCGGAGAATGACCATT (herein referred to as sh2) and shNeg (15). For lentiviral
production, 8 x 105 293T cells were co-transfected with pCMV-VSV-G, pCMVΔR8.2, and
pLKO.1-puro constructs using Fugene 6 (Promega). Forty-eight hours post-transfection, viral
supernatants were collected. PLKO.1 hygro shRNA constructs against Rictor and Raptor were
generated by subcloning hygromycin in place of puromycin within the pLKO.1-constructs.

Immunofluorescence and confocal microscopy
MCF10A acini were grown in 8 well chamberslides and at the indicated time point were fixed
with 4% paraformaldehyde (PFA) in PBS for 30 minutes at room temperature. Slides were
washed three times (15 minutes each wash) at room temperature in 100 mM glycine in PBS and
subsequently permeabilized with 0.05% Tween 20 in PBS, pH 7.4 for 20 minutes. Fixed acini
were blocked in IF buffer (0.2% Triton X-100, 0.1% BSA-radioimmunoassay grade from Sigma
Aldrich, 0.05% Tween 20 in PBS, pH 7.4) and 10% goat serum for 1.5 hours at room
temperature and then blocked in secondary block containing IF buffer + 10% goat serum +
20ug/mL goat anti-mouse IgG F(ab’)2 fragment specific (Jackson ImmunoResearch, Cat. 115006-006) in a humidified chamber for 30 minutes. Fixed acini were then stained with 1:100
primary antibody in IF buffer + 10% goat serum + 20ug/mL goat anti-mouse IgG F(ab’)2.
Primary antibodies were as follows: rabbit anti-Ki67 (Cell Signaling, 9129), rabbit-anti cleaved
caspase 3 (Cell Signaling, 9579), rat anti-integrin alpha 6 (Millipore, MAB1378) and rabbit antigiantin (Covance, PRB-114C). The following day the slides were washed three times in IF buffer
for 20 minutes each and incubated with a secondary antibody (conjugated to Alexa Fluor 488 or
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594) diluted in IF buffer +10% goat serum for 40 minutes at room temperature in a humidified
chamber. Slides were washed three times in IF buffer for 20 minutes each and then incubated
with 1 µM TOPRO3 iodide (Molecular Probes) in PBS for 10 minutes at room temperature in a
humidified chamber. Slides were then washed with PBS once for 10 minutes and mounted with
Prolong Antifade mounting medium (Molecular Probes). Images were obtained using an
Olympus FV-500 confocal microscope with a 20X water objective. Images were processed using
the Olympus FLUOVIEW Ver.2.1a Viewer and ImageJ software. For Ki67 and cleaved caspase
3 evaluations, a total of 10 fields with at least 4 acini per field were acquired and then analyzed
as indicated.

Acini diameter quantification and statistics
Size analysis was performed using a haemocytometer and ImageJ software for each brightfield
image. At least 50 acini from a single field of view were analyzed for acini diameter. The
Student’s t-test was used for statistical analysis.

Immunoblotting
Harvested cells were re-suspended and sonicated in radioimmunoprecipitation assay (RIPA)
buffer (50mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic
acid) containing protease and phosphatase inhibitors (1mM phenylmethylsulfonyl fluoride
(PMSF), 0.4 U/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM β–glycerophosphate,
0.1 mM NaF, 0.1 mM NaVO4). Proteins (30 to 80 g) were fractionated on 10% Tris-HCl,
Criterion Precast Gel (Bio-Rad). Separated proteins were transferred onto polyvinylidene
difluoride (PVDF) membranes (Millipore), and probed with the following antibodies: rabbit antiDAPK3/ ZIPK (abcam, ab51602 and for K42A Cell Signaling, 2928)), rabbit anti-β catenin
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(Santa Cruz, H-102), mouse anti-phospho-p70/p85 (Cell Signaling, 9206), rabbit anti-p70/p85
(Cell Signaling, 2708), rabbit anti-phospho-pS6 (Cell Signaling, 2215), mouse anti-S6 (Cell
Signaling, 2317), rabbit anti-GAPDH (Sigma-Aldrich, G9545), rabbit anti-phospho-T308 AKT
(Cell Signaling, 9275), mouse anti-AKT (Cell Signaling, 2920), rabbit anti-phospho-ERK (Cell
Signaling, 4370), rabbit anti-Actin (Sigma-Aldrich, A2066), mouse anti-RAPTOR (Santa Cruz,
sc-81537) and rabbit anti-RICTOR (Cell Signaling, 2140). Secondary horseradish peroxidaseconjugated anti-rabbit or anti-mouse antibodies (Sigma-Aldrich) were added and ECL Western
Blotting Substrate or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo
Scientific) were used to visualize protein bands.

Soft agar assay
MCF10A cells were first infected with HRasV12, shNeg, sh1, or sh2 expressing lentivirus and
then selected in puromycin (1 g/ml) until canaries were dead. Following drug selection, 1 x 104
stables cells were seeded in 6-well plates, and the cells were fed with fresh media twice a week.
After 3 weeks, plates were stained with crystal violet overnight, washed and colonies were
manually counted.
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2.3 Results
DAPK3 depletion augments acini morphogenesis
To further investigate additional mechanisms by which DAPK3 exerts tumor suppressive
functions, we performed stable shRNA knockdown of DAPK3 in MCF10A cells grown on
Matrigel using two independent hairpins.

As discussed previously, this model permits

interrogation of acini architecture development, which undergoes a series of highly conserved
temporally-concerted biochemical and phenotypic events. First, loss of DAPK3 significantly
enhances acini diameter by approximately 37+10 % as compared to negative control shRNA at
day 8 (Figure 1A, B). Diameter enhancement was observed as early as day 4 and continued to
increase over time while the negative control plateaued at later time points. Interestingly,
DAPK3 depletion does not enhance anchorage independent growth of MCF10A cells growth in
soft agar (Figure 2).

Loss of DAPK3 results in enhanced acini proliferation and apoptosis
It has been well established that size and morphogenesis of MCF10A acini is dependent
on coordinated proliferation and apoptotic programs. To understand which of these processes
was perturbed in DAPK3 knockdown structures, we performed confocal immunofluorescence
microscopy on acini structures. DAPK3-depleted structures contained, on average, significantly
more Ki67+ cells compared to negative control (Figure 3). Interestingly, loss of DAPK3 also
augmented cleaved caspase 3-positive acini relative to negative control (Figure 4). This was
additionally confirmed by ethidium bromide uptake in live MCF10A acini which also indicated a
significant increase in cell death in DAPK3 depleted structures (Figure 5). Thus, while there was
a net increase in acinar size, we hypothesize that as the shDAPK3 structures underwent
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hyperproliferation, more cells lost contact with the ECM and as a result underwent apoptosis, a
phenomenon which has been observed elsewhere (16).

Of note, we did not observe any

alterations in acini apical or basolateral polarity as indicated by proper localization of giantin and
integrin α6, respectively (Figure 6 A, B).

DAPK3 overexpression disrupts normal acini formation
To determine if DAPK3 overexpression impacts acinar morphogenesis, we stably
overexpressed DAPK3 fused to GFP in MCF10A cells that were subsequently grown in 3D.
Despite a large degree of toxicity observed in the packaging cells, we were able to achieve stable
populations of MCF10A cells that survived selection. However, we were not able to achieve high
overexpression of DAPK3 most likely due to overexpression toxicities in both target and
packaging cells that are commonly observed across several cell types (2,17). Additionally, this
expression was lost over time indicating negative selection for sustained high level expression of
DAPK3.

Given these technical challenges, structures that maintained overexpression (as

indicated by GFP fluorescence) displayed a dramatic and significant decrease in structure size
compared to empty-GFP vector alone (Figure 7A, B). We also attempted to determine if this
decrease in size was dependent on DAPK3 kinase activity but we were unable to achieve stable
overexpression of a previously characterized kinase deficient point mutant (K42A) fused to GFP
(data not shown).

However, stable overexpression of an unfused K42A mutant exhibited

microscopic colony growth in soft agar highly similar to negative control, while a significant
decrease was observed in stable cells overexpressing wildtype DAPK3 (Figure 8), consistent
with growth inhibiting-dependence on kinase activity.
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DAPK3 negatively regulates mTOR-S6K-S6 signaling with no effect on ERK
or AKT activation
To identify the pathways functionally regulated by DAPK3 we initially compared our
structural phenotypes to that reported in the literature. Several groups have shown that enhanced
mTOR activity leads to acini with similar abnormalities observed upon loss of DAPK3 (18-20).
Indeed, upon loss of DAPK3 in MCF10A cells grown in 2D culture we observed an increase in
phosphorylation of S6 (P-S6) and both p70 and p85 S6K1 isoforms (herein referred to as P-S6K)
when stimulated with EGF or insulin (Figure 9). We additionally observed an increase in P-S6
from MCF10A cells depleted of DAPK3 that were grown in 3D for 6 days (Figure 10). Of note,
we did not observe an increase in ERK or AKT signaling (Figure 10)

Loss of DAPK3 influences proper acini morphogenesis through mTORC1
To further confirm that this enhanced mTOR signaling was functionally relevant, we
treated established negative control and DAPK3-depleted acini with 100 nM rapamycin once
starting at day 4. 4 days later we observed that rapamycin had no significant effect on the
diameter of the negative control. However, acini stably transduced with both independent
DAPK3 hairpins displayed a significant sensitivity to rapamycin treatment (Figure 11 A).
Additionally, established shDAPK3 acini treated with increasing concentrations (100 nM, 10 µM
and 50 µM) of the PI3K inhibitor LY294002 displayed similar increased sensitivity to the drug
compared to negative control (Figure 11B).
To further delineate how DAPK3 regulates mTOR for proper acini morphogenesis, we
stably knocked down DAPK3 and RICTOR or RAPTOR using previously reported hairpins (21).
Interestingly, we observed that loss of DAPK3 and RAPTOR blunted the increased acini size
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whereas loss of RICTOR did not rescue the phenotype (Figure 12A). Additionally, loss of
RAPTOR by itself had a profound impact on acini formation whereas knockdown of RICTOR
did not.

Clinically observed down regulation of DAPK3 mRNA
Finally, we wanted to confirm that our cell culture observations mimic that seen in actual
patients using the Oncomine database (www.oncomine.org).

Indeed, DAPK3 mRNA is

significantly downregulated in ductal breast carcinoma in situ (DCIS) and invasive ductal breast
versus normal breast and DCIS controls, respectively (Figure 13 A, B). DAPK3 mRNA is also
significantly downregulated in pancreatic adenocarcinoma as well as melanoma versus normal
controls (Figure 13 C, D).

2.4 Discussion
Herein we have shown that loss of DAPK3 leads to increased acini size, enhanced acini
proliferation and apoptosis without disrupting apical-basolateral polarity. Conversely, stable
overexpression of DAPK3 inhibits acini morphogenesis and is relatively toxic to cells. Loss of
DAPK3 augments acini morphogenesis through mTOR-S6 signaling. This regulation appears to
be downstream of the mTOR pathway as loss of DAPK3 enhanced S6K-S6 phosphorylation, but
not ERK or AKT. Furthermore, this regulation is specific to mTORC1 and not mTORC2 as only
loss of RAPTOR (and not RICTOR) partially rescues the augmented acinar morphogenesis
observed upon loss of DAPK3.

Collectively, our data reveal a novel tumor suppressive

mechanism for DAPK3 through its inhibition of mTOR-S6K-S6 signaling (Figure 12B)
It is well known that the mTOR pathway plays an important role in cancer cell growth,
survival and proliferation (22). As such, activation of the pathway is controlled by several
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upstream tumor suppressors including LKB1 and NF1 (23,24). mTOR is the fundamental
catalytic component of two distinct complexes, rapamycin-sensitive mTORC1 and rapamycin
insentitive-mTORC2, each of which is composed of distinct protein complexes that alter the
protein-protein interactions, subcellular localization, activity and substrate specificity of the
active complex. Genetic ablation of key scaffolding proteins RAPTOR or RICTOR effectively
prevents signaling through mTORC1 and mTORC2, respectively. Our data indicates that the
increased acini size observed upon loss of DAPK3 is uniquely sensitive to mTORC1 inhibition.
Indeed, mTORC1 has been shown to play a large role regulating many of the processes required
for acini morphogenesis and thus these observations are expected.
Interestingly, several other members of the DAPK tumor suppressor family are known to
regulate translation and regulate or be regulated by the mTOR pathway. Conflicting reports
reveal that DAPK1 disrupts TSC1-TSC2 association thereby enhancing mTOR activation and
negatively regulates protein translation through an inhibitory phosphorylation at S235/236 of S6
(25,26). However, Roux et al. revealed RSK-dependent phosphorylation at S235/ 236 actually
promotes translation through assembly of the translational pre-initiation complex (27). DRAK2
phosphorylates S6K kinase in vitro and in vivo (28). DAPK3 is phosphorylated by DAPK1 in
vitro and this DAPK1-DAPK3 kinase cascade has been shown to inhibit transcript-specific
translation through phosphorylation of the ribosomal protein L13a and activation of an
translational inhibitor complex known as the interferon-gamma activated inhibitor of translation
(GAIT) complex (17,29). These observations along with our data implicate the DAPK family as
important regulators of translation and mTOR signaling.
Overall, the research presented herein indicates that suppression of mTOR-S6K-S6
signaling by DAPK3 maintains proper acini morphogenesis and that these mechanisms
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potentially exist in several human cancers where DAPK3 mRNA is downregulated. Further
studies are necessary to uncover the biochemical mechanism by which DAPK3 inhibits the
mTOR pathway. Our data suggests that the kinase activity of DAPK3 is required and thus
DAPK3 potentially induces an inhibitory pathway through activation of an mTOR inhibitor or
inhibition of an mTOR activator. Interestingly, we did not observe an increase in soft agar microcolony growth in MCF10A stably expressing the kinase dead mutant relative to empty vector
control. This may indicate cell line specific effects as other cell lines have previously shown a
dominant negative effect on proliferation with this mutant (2).
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2.5 Figures
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Figure 1. Loss of DAPK3 augments MCF10A acini. (A) MCF10A cells stably expressing shNeg
or two independent DAPK3 hairpins (sh1, sh2) were cultured on Matrigel for 12 days.
Brightfield images show representative structures at specific time points. (B) Mean diameter of
MCF10A acini stably expressing respective hairpins at various time points. Depicted here is a
representative of three independent experiments. Error bars indicate 95% confidence intervals. *,
P < 0.005 relative to control.
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Figure 2. Loss of DAPK3 expression does not promote anchorage independent growth of
MCF10A cells. Stable MCF10A cell lines were grown in soft agar for 3 weeks.
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Figure 3. DAPK3 depleted acini exhibit increased proliferation.

Fluorescent confocal

microscopy analysis of acini stained for Ki67 (green) and DNA (blue). Depicted here is a
representative of two independent experiments. Error bars indicate 95% confidence intervals. *,
P < 0.001.
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Figure 4. DAPK3 depleted acini exhibit increased apoptosis. Fluorescent confocal microscopy
analysis of acini stained for cleaved caspase 3 (CC3, green) and DNA (TOPRO3, blue). Depicted
here is a representative of three independent experiments. Error bars indicate 95% confidence
intervals. *, P < 0.0001 relative to control.
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Figure 5. DAPK3 depleted acini display increased ethidium bromide positive cells. Live
MCF10A acini stably expressing negative control or shDAPK3 hairpins were incubated with 1
µg/ mL ethidium bromide at day 6 and subsequently analyzed. Shown here is a representative of
three independent experiments. Error bars indicate 95% confidence intervals. **, P < 0.0001.
Scale bar, 100µm.
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Figure 6. DAPK3 depleted acini show proper localization of apical-basolateral markers. Day 6
structures were analyzed for proper localization of apical marker giantin (red, top panel) and
basolateral marker integrin α6 (red, bottom panel) along with DNA stain (TOPRO3, blue). Scale
bars, 100µm.
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Figure 7. Stable overexpression of DAPK3 inhibits acini growth. (A) Fluorescent microscopy of
live acini stably overexpressing GFP or GFP-DAPK3 at day 8. Scale bar, 100µm. (B) Size
analysis of day 8 GFP+ acini from GFP or GFP-DAPK3 stable structures. Error bars indicate
95% confidence intervals of three combined independent experiments.*, P < 0.0001 relative to
control.
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αDAPK3
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Figure 8. Stable overexpression of a DAPK3 kinase dead point mutant does not alter
microscopic colony growth. MCF-10A cell stably overexpression empty vector, DAPK3 or
K42A were grown in soft agar for 3 weeks and then total numbers of microscopic colonies were
counted. Shown here is a representative of three independent experiments. Error bars indicated
95% confidence intervals.*, P< 0.001.
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Figure 9. Increased activation of mTOR specific S6K-S6 pathway upon loss of DAPK3 in stable
MCF10A cells. Western blot analysis of serum starved MCF10A stable cells grown in 2D and
treated with media, EGF (10ng/ mL) or insulin (10 ug/mL) for 24hrs. Shown here is a
representative blot of three independent experiments.
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Figure 10. Increased phosphorylation of S6 upon loss of DAPK3 in stable MCF10A acini.
Western blot analysis of MCF10A acini grown on Matrigel for 6 days. Shown here is a
representative blot of two independent experiments.
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Figure 11. DAPK3 depleted acini are sensitive to rapamycin and LY294002 treatment. (A)
Analysis of MCF10A acini grown for 4 days and then treated with 100 nM rapamycin for 4 days.
Shown here is a representative of two independent experiments. Error bars indicate 95%
confidence intervals. **, P<0.0001. *, P<0.005. (B) Analysis of MCF10A acini grown for 4 days
and then treated with varying concentrations of LY294002 (vehicle, 100 nM, 10 µM, or 50 µM)
for an additional 4 days. Error bars indicate standard deviations of three combined independent
experiments. *, P<0.03.
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Figure 12. DAPK3 inhibits acini morphogenesis through mTORC1/ RAPTOR. (A) Analysis of
day 4 acini from MCF10A cells stably expressing various hairpins. Shown here is a
representative of two independent experiments. Error bars indicate 95% confidence intervals. *,
P<0.01. (B) Depiction of negative regulation of the mTORC1-S6K-S6 pathway by DAPK3.
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Figure 13. Clinically observed downregulation of DAPK3 mRNA in breast and various cancers
from the Oncomine database (www.oncomine.org). (A) DAPK3 mRNA is significantly
decreased in ductal carcinoma in situ (DCIS) relative to normal patient samples. *, P<0.002 (B)
DAPK3 mRNA is significantly decreased in aggressive breast cancer patient samples compared
to normal patient samples. *, P<0.04. (C) Significant decrease in DAPK3 mRNA expression in
pancreatic ductal adenocarcinoma (PDA) relative to normal patient samples. *, P<0.01. (D)
Significant decrease in DAPK3 mRNA expression in melanoma relative to normal patient skin
samples. *, P<0.001.
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CHAPTER 3: DAPK3 IS REQUIRED FOR EARLY MOUSE
DEVELOPMENT & DISPLAYS DISTINCT EXPRESSION
PATTERNS IN EMBRYONIC AND ADULT TISSUES
3.1 Introduction
The serine/ threonine death-associated protein kinase (DAPK) family is a relatively novel
kinase family. The DAPK family is known to regulate smooth muscle contraction, cell-cell
adhesion, cytoskeleton dynamics, inflammation, and cardiovascular functions as well as tumor
suppression through regulation of caspase-dependent and -independent cell death, proliferation
and autophagy (1). The DAPK family contains 5 members, including DAPK1 , DRP-1 (DAPKrelated protein 1), DAPK3 (also known as zipper interacting protein kinase (ZIPK), DRAK-1
and DRAK-2 (DAPK-related apoptosis-inducing protein kinase-1 and -2), which all share high
homology within their kinase domain (1). Compared to the prototypical family member DAPK1,
relatively little is known about DAPK3. DAPK3 contains an N-terminal kinase domain that
shares 80% amino acid homology with the prototypical DAPK1. It differs from other family
members by the presence of a C-terminal leucine zipper motif and the absence of a calmodulinregulated (CaM) domain and death domain. Similar to other family members, DAPK3 is
considered to be a putative tumor suppressor. Overexpression of DAPK3 in mammalian cells
results in cell death and cell cycle inhibition while kinase inactivating mutations along with
recurrent deleterious somatic mutations are observed in lung and breast cancers, respectively (2–
4). Additionally, DAPK3 has been shown to interact with and/ or phosphorylate various proteins
in vitro including ATF4, AATF, Daxx, Par-4, STAT3, NLK, and AR (2,4–9).
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Currently, a fundamental understanding of DAPK3 is limited due to the lack of a
knockout mouse. Commonly used model systems such as Caenorhabditis elegans,
Saccharomyces cerevisiae, and Drosophila melanogaster lack clear DAPK3 orthologues,
thereby hindering traditional genetic interrogation. Uncovering the physiological contributions
of DAPK3 is crucial to understanding the clinical and basic research observations described
above. Furthermore, DAPK1 and DAPK3 inhibitors are currently under development for use in
smooth muscle related disorders (10,11).

Thus, a DAPK3 deficient animal may indicate

potentially deleterious phenotypes associated with loss of a functional DAPK3 protein.
Given these gaps in the fundamental understanding of DAPK3 we generated a DAPK3
knockout mouse using a gene trap embryonic stem cell line acquired from the International Gene
Trap Consortium. Although mechanistically different than traditional flx/ flx knockout strategies,
gene traps have provided a cost-effective and high throughput means to functionalize the mouse
genome (12). Described herein is the generation and characterization of the unexpected early
lethality of DAPK3 null mice. Additionally, we identified a distinct and localized pattern of
Dapk3 promoter activity within the developing heart and nervous system. We also observed that
the Dapk3 promoter is active in the myenteric plexus of the large intestine and breast epithelium
of adult mice. Collectively these results identify a fundamental role for DAPK3 in mouse
development and identify distinct expression patterns in developing and adult animals.

3.2 Materials & Methods
Generation of DAPK3 KO Mice
The pre-confirmed BayGenomics ES line YTA407, was acquired from the International Gene
Trap Consortium and injected into albino C57BL/6 mice using traditional techniques. One initial
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founder chimaera was chosen due to high degree chimerism as assessed by coat color and
subsequently backcrossed onto a pure albino C57BL/6 background (N6 as determined by speed
congenics). Polymerase chain reaction genotyping was performed using the following primers:
Forward

5’

GTGTGCATATGTGTCTTAGTCACAGCAC,

Reverse

5’

GGCGATTAAGTTGGGTAACGCCAG, Reverse 5’ GACAGTATCGGCCTCAGGAAGATC
G.

Southern Blot
For each southern blot, 5 µg of isolated DNA was digested with SphI overnight at 37°C.
Digested DNA was run on a 1.0% agarose gel and subsequently transferred to a charged nylon
membrane after depurination, denaturation and neutralization. After crosslinking, the transfer
membrane was blocked in pre-heated Hyb Plus Buffer (Sigma) and salmon sperm at 68°C for 2
hours with constant agitation. Polymerase chain reaction was used to generate the following
southern

probes

from

heterozygous

genomic

GACTCGATGGCTGAGGACGGTACGAATG,
CTCAAGAGGCTGAGGCTGGAGGATTAAACA;
CACGGAGAATCCGACGGGTTGTTACTCGC,

DNA,

Forward,

Internal:
Reverse,

External:

5’
5’

Forward,

Reverse,

5’
5’

GCACATCTGAACTTCAGCCTCCAGTAC. After gel purification, probes were labeled with
50 µCi of 32αP-dCTP (Perkin Elmer) using the Roche Random Prime Labeling Kit and then
cleaned on an Ambion Column. Hybridization occurred overnight at 68°C with constant
agitation. The following day, membranes were washed and subsequently imaged using a
Phospho-screen and Storm 860.
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Blastocyst Isolation and Genotyping
E3.5 embryos were harvested from mated super ovulated females (<6 weeks). Whole genome
amplification was then performed on individual blastocysts (Sigma WGA4) followed by
standard PCR genotyping as described above.

Generation of Embryonic Stem (ES) Cell Lines
E3.5 embryos were harvested from mated super ovulated females (<6 weeks). Isolated
blastocysts were then seeded on pre-plated gamma irradiated MEF feeder cells in a 96 well plate.
Prior to seeding the blastocysts, standard MEF media was changed to the following primary ES
media: KO DMEM (Gibco), 7.5% KO Serum replacement (Invitrogen), 7.5% ES tested FBS
(Hyclone), non-essential amino acids (Gibco), L-glutamine (Gibco), 0.1 mM β-mercaptoethanol,
1,000 Units/ mL leukemia inhibitor factor (LIF), 3 µM CHIR99021, 1 µM PD0325901, 10 µM
SB431542 and penn/ strep. Plated blastocysts were maintained at 37 C, 5% CO2. Fresh ES media
was supplemented every 2 days. When a large portion of the inner cell mass had grown out of
the attached blastocyst the well was trypsinized and plated onto a pre-plated MEF layer in a 96
well plate similar to before. Once ES colonies were clearly apparent the culture was serially
passaged up to a T25 at which point multiple freeze downs were made.

Quantitative PCR (qPCR)
The TaqMan Assay was used to quantify Dapk3 mRNA isolated (RNAeasy) from genotype
confirmed ES lines. FAM conjugated probes were manufactured by Life Technologies/ Applied
Biosystems that were complimentary and spanned exons 8-9 of the endogenous mouse Dapk3
locus (Mm00492083_g1). A VIC conjugated mouse actin probe was used as a control.
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Immunoblotting
Harvested cells were re-suspended and sonicated in radioimmunoprecipitation assay (RIPA)
buffer (50mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic
acid) containing protease and phosphatase inhibitors (1mM phenylmethylsulfonyl fluoride
(PMSF), 0.4 U/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM β–glycerophosphate,
0.1 mM NaF, 0.1 mM NaVO4). Proteins (30 to 80 g) were fractionated on 10% Tris-HCl,
Criterion Precast Gel (Bio-Rad). Separated proteins were transferred onto polyvinylidene
difluoride (PVDF) membranes (Millipore), and probed with the following antibodies: rabbit antiDAPK3/ ZIPK (Cell Signaling, 2928), rabbit anti-β catenin (Santa Cruz, H-102), rabbit antiActin (Sigma-Aldrich, A2066) and rabbit IGG fraction against β-galactosidase (MP, 08559761).

Tissue prep, fixation and β-galactosidase activity
Embryos were fixed in 0.2 % glutaraldehyde for 20 minutes at 4°C and then washed twice for 10
minute in wash buffer (0.1M phosphate buffer pH7.3, 2 mM MgCl2, 5 mM EGTA, 0.01%
sodium deoxycholate and 0.02% NP40). Washed embryos were then stained overnight at 37°C in
the following staining solution: wash buffer, 5 mM potassium ferrocyanide, 5 mM potassium
ferricyanide and 1 mg/ mL Xgal. The following day embryos were fixed in 10%
paraformaldehyde for 30 minutes and then washed 3 times in PBS for 10 minutes each. Whole
mount photography was performed after embryos were serially incubated in 50%, 75% and 90%
glycerol. For intestinal fixation and β-gal activity, the same protocol was generally followed as
described above.
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Immunofluorescence
Mammary glands from 8 week old female littermates were dissected and fixed in 4%
paraformaldehyde for 1 hour at 4°C. Glands were then washed twice for 5 minutes in PBS at
4°C. Subsequently, glands were immersed in 15% sucrose for 4 hours at 4°C and then 30%
sucrose overnight at 4°C. The following day glands were embedded in OCT and stored at -80°C
overnight. 10 µm sections were placed on Superfrost/ Plus charged slides and stored at -80°C
overnight. For labeling, slides were thawed at room temperature for 10 minutes and then washed
for 5 minutes in PBS to remove OCT residue. Slides were then blocked with 10% donkey serum,
1% bovine serum albumin, 0.2% non-fat dry milk and 0.3% Triton X-100 in PBS for 1.5 hours at
room temperature. Slides were then incubated with respective primary antibodies in blocking
buffer overnight at 4°C in a humidified chamber. The following primary antibodies were used:
rabbit anti-β-galactosidase (MP, 559761) and mouse anti-E-cadherin (BDbiosciences, 610182).
Slides were washed three times for 5 minutes with PBS and then incubated with fluorophore
conjugated secondary antibodies (Alexa Fluor 488 or 594) diluted in blocking buffer for 1 hour
at room temperature in the dark. Slides were then washed three times for 5 minutes in PBS and
then mounted in DAPI-containing Vecta Shield and imaged using a Nikon Eclipse Ti microscope
at the same exposure settings and subsequently processed using ImageJ software.

3.3 Results
Generation of DAPK3 null mice
In an attempt to understand the overall in vivo contribution of DAPK3, we created a
constitutive DAPK3 knockout mouse using a pre-confirmed gene trap ES line from the
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International Gene Trap Consortium. The gene trap (Gt) is composed of a 5’ splice acceptor site
followed by a β galactosidase- neomycin fusion (βgeo) and a polyA tail (Figure 1 A). Initially
we confirmed that the locus and the entire gene trap were intact and incorporated as a single
insertion through Southern Blot analysis using both external probes and internal probes on a
single clonal population of YTA407 ES cells (Figure 1 B). These ES cells were then used to
generate a mouse using traditional blastocyst injection and animal husbandry techniques that
were successfully genotyped as seen in the representative genotyping polymerase chain reaction
(PCR) (Figure 1 B, lower panel).

Characterization of early embryonic lethality of DAPK3 null mice
Overall, heterozygous animals appear to develop and grow normally with no overt
phenotypes under standard laboratory conditions (Figure 1 C). However, we were unable to find
homozygous gene trap animals on a mixed 129Ola or backcrossed C57BL/6 (N5) background
(Table I). We were also unable to locate homozygous gene trap embryos at E12.5, 10.5, and 8.5
despite near Mendelian ratios for wild type and heterozygous embryos, indicating early
homozygous lethality (Table I).

We also observed the presence of several sites of fetal resorption on uteri extracted from
heterozygous crosses versus heterozygous and wild type crosses (Figure 2 A). We were able to
isolate and genotype homozygous gene trap blastocysts at E3.5 (Figure 2 B) indicating that
lethality was potentially occurring post-implantation. Furthermore, there was no difference in
distribution of homozygous embryos across blastocyst, morula and pre-morula (Figure 2 C).
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In order to confirm that the gene trap was functional, we used both quantitative PCR
(qPCR) and immunoblotting analysis. qPCR performed on mRNA extracted from established
and genotype-confirmed primary embryonic stem cells indicated a gene-dose dependent decrease
in the expression of Dapk3 mRNA. Specifically, a heterozygous ES lines expressed
approximately 50% Dapk3 mRNA and several homozygous gene trap lines expressed very little
Dapk3 mRNA relative to a wild type control (Figure 3 A).
Next to further confirm a functional gene trap, we attempted to visualize differences in
DAPK3 protein expression from established primary ES lines. After several discussions with
technical staffs at various commercial antibody manufacturers we were unable to locate
antibodies that were able to detect endogenous levels of the mouse 53 kDa DAPK3 protein
(Figure 3 B). A representative inaccurate antibody is provided that recognized a single protein
shown to repeatedly migrate lower than 50 kDa. Despite these technical setbacks we were able to
utilize a β-galactosidase specific antibody that displayed a reactive band that migrated at the size
calculated to match a protein produced from the fusion of the first 2 exons of DAPK3 and the
remaining β-galactosidase-neomycin cassette produced by the gene trap (Figure 3 B).

Embryonic and adult expression patterns of the mouse Dapk3 promoter
Taking advantage of the functional βgal expressed under the endogenous Dapk3
promoter we characterized the expression patterns of Dapk3 during the development of
heterozygous mice. We observed distinct and strong βgal activity in the developing heart of E8.5
and E10.5 embryos (Figure 4A, B). Additionally, E10.5 heterozygous embryos displayed
localized activity within the developing notochord (Figure 4B). As expected, no β-gal activity
was observed in developing wildtype littermates (data not shown). We were also able to
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visualize localized activity in the developing arms, legs and notochord of E13.5 fetuses (Figure
4 C).
We next attempted to visualize Dapk3 promoter activity through β-gal activity and
immunofluorescence techniques in the large intestine and breast of adult heterozygous mice.
Strong and distinct β-gal activity was observed in the myenteric plexus (gastrointestinal nervous
system) of the large intestine (Figure 5 A) with no β-gal activity observed in wildtype littermate
controls (data not shown). Additionally, immunofluorescence using a β-gal specific antibody
indicated that the Dapk3 promoter is active in epithelial cells of the mouse mammary gland
(Figure 5 B).

3.4 Discussion
Our work has identified that DAPK3 is necessary for early mouse development and that
the Dapk3 promoter displays distinct organ and cellular promoter expression patterns. Our
analysis indicates that DAPK3 deficient blastocysts are able to implant but subsequent
development is problematic. These results were unanticipated given that DAPK1 null mice
develop normally as indicated by their overall health in common laboratory settings (13). This
dichotomy raises a number of questions regarding signaling redundancies between DAPK and
DAPK3 and suggests important DAPK-independent developmental functions for DAPK3.
Clearly, future investigation is required and our work supports the development of conditional
DAPK3 knockout mice.
Our work also suggests that mouse DAPK3 exhibits localized expression in the
developing heart and nervous system. These expression patterns and our developmental
observations are of potential relevance to human development as human DAPK3 resides on
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19p13.3, a region shared by 7 other genes that when deleted results in face and heart structure
abnormalities, along with intellectual disability and development delay(14).
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3.5 Figures

B

A

C

Figure 1. Generation and characterization of DAPK3 knockout mice. (A) Schematic
representation of the Dapk3Gt(YTA407)Byg locus. (B) Southern blot of a correct positional and single
integration with the endogenous dapk3 locus from the YTA407 ES line. A representative PCR
genotyping from adult mice is also included. (C) Gross body weight of wildtype versus
heterozygous adult mice.
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A

Dapk3+/+

Dapk3Gt/Gt

B

C

Figure 2. (A) The appearance of increased resorbed E10.5 fetuses (red arrows) in uteri extracted
from heterozygous crosses (top) versus wildtype-heterzoygous crosses (below). (B) Brightfield
images of genotype confirmed blastocysts isolated from heterozygous crosses. (C) Distribution
of early stage homozygous gene trap embryos.
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A

B

+/+ +/+

-/-

-/-

-/-

Figure 3. (A) qPCR analysis of Dapk3 mRNA extracted from genotype confirmed primary ES
cells. (B) Western blot analysis of expression of DAPK3-βgeo protein product in wildtype and
homozygous gene trap primary ES lines. (C) Embryonic developmental stage distribution of
genotype confirmed homozygous gene trap embryos.
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A
C

E13.5

B

Figure 4. (A) Distinct and localized βgal activity in the developing heart of genotype confirmed
heterozygous E8.5 embryo (red arrows). Similar specific localization of βgal activity in the
developing heart and notochord (red arrows) from genotype confirmed heterozygous E10.5
embryos. (C) Activity also observed in the developing arms, legs and notochord of E13.5 fetuses.
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A

B
+/+

+/-

A

DAPI LacZ E-Cad

DAPI LacZ E-Cad

Figure 5. (A) Distinct β-gal activity in the myentereic plexus of the large intestine from 10 week
old heterozygous animals. Shown here is an H&E fusion for topographical comparison. (B) The
dapk3 promoter is active in the epithelia of mouse mammary glands as visualized using
immunofluorescence.
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3.6 Table
Table I. Ratios of various genotypes in embryos and adult mice.

Genotype

E8.5

E10.5

E12.5

129Ola

C57BL/6

+/+

4

2

4

39

8

+/Gt

4

5

6

68

13

Gt/Gt

0

0

0

0

0
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CHAPTER 4: CONCLUSIONS & FUTURE DIRECTIONS
4.1 Conclusions
Collectively, the data described herein has revealed a novel mechanism by which DAPK3
exerts its potential tumor suppressive functions and additionally identifies an unexpected role in
mouse development. Specifically, we have identified that DAPK3 negatively regulates mTOR
signaling which has functional implications for breast tumorigenesis. Furthermore, complete loss
of DAPK3 leads to early lethality (E 4.5-6.5) in mouse embryos. The Dapk3 promoter is active
in the developing heart and nervous system as well as the gastrointestinal myenteric nervous
system and breast epithelium of adult animals. Our studies suggest that loss of DAPK3
expression in the breast epithelium can facilitate breast cancer development as reduced DAPK3
expression is observed in DCIS and aggressive breast cancers relative to normal and DCIS,
respectively. Overall, both the MCF10A 3D morphogenesis phenotypes and mouse
developmental defect (s) argue against the clinical use of DAPK3 inhibitors that are currently
under development and support future studies.

4.2 Future Directions
Despite these important discoveries there remains much to be known about DAPK3 and
other members of the DAPK family. Future DAPK3 research should involve a detailed
biochemical evaluation of mTOR-S6K-S6 inhibition, identification of functionally relevant
substrates, identification of translationally repressed target mRNAs, and subsequent development
of more exquisite and appropriate genetically engineered mouse models for breast cancer
inquiries. A general discussion of these future studies is discussed in detail below.
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Based on the data presented above, DAPK3 negatively regulates S6K-S6 signaling in a
potentially kinase-dependent manner. First, kinase-dependency should be confirmed. As
discussed, initial attempts involved stably overexpressing a kinase dead mutant (K42A).
However, these failed potentially due to combined instability of the point mutant and an Nterminal GFP fusion. Subsequent attempts to ameliorate this set back could involve using
different fluorescence proteins (mCherry, YFP) and different DAPK3 kinase deficient mutants in
various N- and C-terminal orientations. Additional studies are also warranted within different
cancer cell lines to determine the ubiquity of DAPK3 repression of mTOR signaling. This
includes a breast cancer-focused panel of benign and malignant breast cancer cell lines along
with different breast cancer subtypes (luminal A/B, triple negative, and Her2) and also additional
malignant cell lines derived from non-breast tumors. The differential growth-factor or nutrient
deprivation response of various cell lines (lacking or overexpressing DAPK3) should also be
evaluated within the mTOR pathway. While my studies have determined that DAPK3 regulates
mTOR-S6K-S6 signaling potentially downstream of ERK/ AKT mediated activation, additional
studies should confirm 4E-BP1 regulation. This will help to determine if these is a general
mechanism or if it is specific to S6K-S6 regulation.
Beyond general pathway dissection, further biochemical studies are warranted to identify
the DAPK3 phosphorylation substrate(s) (herein referred to as protein X) and how this
negatively regulates the mTOR pathway. While our data indicates potential DAPK3 mediated
inhibition downstream of mTOR, this should be confirmed through evaluation of upstream
components. Initial cursory investigations should include surveying known inhibitory
phosphorylation sites within the mTOR pathway that can potentially be directly or indirectly
induced by DAPK3. This could include TSC2 activating phosphorylations by AMPK (T1227
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and S1345) (1) or GSK3β (S1337 and S1341) (2). Downstream of TSC1/2, RheB GTPase
activity should be evaluated. Additionally, TSC1-TSC2 interaction and differential
phosphorylation of S6K should be evaluated given that several other DAPK family members are
known regulate S6K/ S6. These approachable studies will be able to determine if commonly
regulated nodes within the mTOR pathway are impacted by DAPK3 but screens of some sort
will be required to identify less obvious regulators.
To date, the molecular mechanisms of DAPK3 have only been surveyed by protein
interactions assays that involve the ectopic expression of DAPK3. Additionally, novel
phosphorylation substrates have been identified through primary interaction assays as well.
Alternative approaches to detail the DAPK3-mTOR-S6K-S6 pathway using high throughput
screens with genetically encoded optical readouts might be inherently flawed due to the
translational-sensitivity of the optical system output. Specifically, identifying a normalization
control that does not respond to alterations in translation would be difficult.
One potential method to define the molecular mechanism by which DAPK3 regulates the
mTOR pathway would be to utilize two dimensional (2D) differential in-gel electrophoresis
(DIGE) proteomic profiling of immobilized metal affinity chromatography (IMAC) enriched
phosphoproteins. This type of phosphoproteomic approach was recently used to identify novel
ERK-MAPK kinase substrates (3) and these services are offered through proteomics scores such
as Siteman Cancer Center-Proteomics Core headed by Dr. Reid Townsend located on the
Washington University Medical Campus. DIGE allows for differential labeling of several
protein populations from different sources to be run in the same gel thereby preventing the
inherent variability in cross comparisons of 2D-PAGE gels.
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This technique could be applied to knockdown and overexpression experiments to
simultaneously identify substrates based on respective converse outputs from each assay. To
reduce background labeling and enrich low abundant phosphoproteins, whole cell lysates will be
run over commercially available IMAC columns. Subsequent elutions will be labeled with
spectrally distinct Cy3, and Cy5 dyes. Knockdown and over expression of DAPK3 should reveal
converse phosphorylation events on DAPK3. Individual phosphoprotein populations will be
fluorescently imaged within the gel and pseudo-colored digital images will be overlaid to
quantitatively measure changes in phosphoprotein status between experiments. Selected gel
features will be selected using DeCyder software, robotically excised, digested and subjected to
liquid chromatography and tandem mass spectroscopy analysis for simultaneous substrate and
phosphorylation site identification. Alternative methods include mass spectroscopy-based semiquantitative liquid chromatography mass spectrometry. Herein, lysates would be collected from
similar cellular conditions, subjected to trypsin digestion, enriched for phosphoproteins using
IMAC, and subjected to HPLC tandem mass spectrometry. Changes in the relative abundance of
specific m/z spikes when compared between treatments will be used to semi-quantitatively
indicate potential differential phosphoprotein status as well as substrate identification.
For technical ease, phosphoprotein populations should be extracted from 2D MCF10A
EGF-stimulation assays similar to those discussed in the western blots above. EGF induces
robust activation of the mTOR system potentially increasing the sensitivity of phosphoproteomic
approaches. After primary identification of putative DAPK3 phosphorylation substrates,
subsequent in vitro phosphorylation assays with DAPK3 and protein substrates should be
performed along with respective point mutant controls (DAPK3 K42A-kinase dead, DAPK3phosphorylation site mutated protein X). Subsequently, protein X-point mutants should be
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overexpressed (S/T/Y->Q or S/T/Y->A) during manipulation of DAPK3 expression to confirm
respective effects on mTOR activation as regulated by DAPK3. After mTOR regulation is
confirmed, if possible, monoclonal antibodies directed against the phospho-protein X should be
used to confirm DAPK3-dependent phosphorylation in vitro and in vivo. Following these studies,
appropriate targets should be functionally confirmed in the 3D MCF10A morphogenesis assay.
It will also be important to further understand the translational program repressed by
DAPK3. Specifically, which mRNA transcripts are translationally repressed by DAPK3. This
might lead to identification of novel oncogenes and further detail the inhibitory mechanism of
DAPK3. To identify which transcripts are translationally upregulated by depletion of DAPK3,
polysome ribosome profiling followed by gene expression analysis will be performed. Increased
transcripts present within polysome fractions will indicate increased transcript-specific
translation. Total mRNA will be collected from 2D MCF10A treated as stated previously and
appropriate polysome fractions will be collected and submitted for gene expression analysis.
This approach is supported by the already reported role of DAPK3 repression of transcriptspecific translational in response to interferon-gamma (4).
It will also be crucial to investigate the functional similarity between human and mouse
DAPK3 by developing and utilizing more exquisite genetically engineered DAPK3 mouse
models. As discussed previously, it has been posited that human DAPK3 and murine DAPK3
(rat and mouse) differ in localization and sub-cellular functional capabilities (5). Interestingly the
authors did not show immunofluorescence localization or nuclear-cytoplasmic fractionation data
for mouse DAPK3 so the exact subcellular localization remains unknown. Our data suggests that
DAPK3 is expressed in the mammary epithelium and clinical evidence suggests its
downregulation can facilitate breast cancer development and progression. Regardless of the
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localization of ectopically expressed DAPK3, endogenous DAPK3 might display a completely
different localization pattern that cannot be evaluated due to lack of appropriate antibodies.
These arguments should not hinder the development of additional mouse models given the data
presented within this dissertation.
To technically approach these questions within the context of mouse models of breast
cancer, one would first need to overcome the early lethality of homozygous null DAPK3 mice
using a conditional genetic system. This could be done using two systems: transplantation or a
transgenic-conditional system. Both approaches would first require the generation of a floxed
Dapk3 mouse such that when Cre-recombinase is conditionally expressed subsequent DAPK3
expression is appropriately ablated. For transplantation mammary glands post-Cre recombination
will have to be transplanted into wildtype donors. In order to distinguish and monitor the
transplanted mammary gland development the conditional mouse and breast tissue will also have
to express a marker (GFP, LacZ) after Cre-recombination. The second approach would involve
crossing the conditional DAPK3 mouse with that of a transgenic mouse that expresses Cre within
the breast under the control of a mammary gland specific promoter such as mouse mammary
tumor virus (MMTV) or whey acidic protein (WAP) promoters. Downsides of each approach
involve troublesome viable transplantation for the former and lack of organ-specific expression
for MMTV/ WAP promoters (6). Results from these studies paired with orthotopic xenografts in
which DAPK3 is depleted will shed light on the extent of DAPK3’s tumor suppressive properties
in accurate physiological contexts. Additionally, these conditional models can be crossed with
other organ/ cancer-specific mouse models to evaluate the functional contribution of DAPK3
alterations to other diseases and cancers.
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Statement of Significance
•

Deciphering the complex molecular interactions between cancer somatic lesions and host
microenvironment are crucial to understanding cancer cell proliferation, migration,
invasion, and immune evasion, and may guide new anti-cancer therapies.

•

Of equal importance as digitized genomics, the next essential challenge is to functionalize
the cancer genome and to correctly capture these molecular mechanisms in their proper
biological context within cancer systems.

•

Molecular imaging with genetically-encoded imaging reporters, especially
bioluminescence, provides a dynamic and noninvasive analysis platform to resolve the
cooperative genetic elements of cancer systems at various temporal and spatial scales.

•

Bioluminescence reporters expressed in live cells and mouse models of cancer have
provided powerful tools to monitor cancer-associated genetic circuits, signaling pathways,
and drug-targeted protein function in vivo.
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Abstract
Bioluminescent imaging (BLI) is a powerful non-invasive tool that has dramatically
accelerated the in vivo interrogation of cancer systems and longitudinal analysis of mouse
models of cancer over the past decade. Various luciferase enzymes have been genetically
engineered into mouse models (GEMMs) of cancer which permit investigation of cellular and
molecular events associated with oncogenic transcription, post-transcriptional processing,
protein-protein interactions, transformation and oncogene addiction in live cells and animals.
Luciferase-coupled GEMMs ultimately serve as a non-invasive, repetitive, longitudinal, and
physiological means by which cancer systems and therapeutic responses can be investigated
accurately within the autochthonous context of a living animal.
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Introduction
Transitioning into the Proper Context
Genomic lesions within incipient cancer cells in collaboration with alterations in the
microenvironment contribute to neoplastic progression (1-3). Tumor cells can modulate the
surrounding microenvironment to promote the progression of cancer through intrinsic oncogenic
pathways. Furthermore, key genetic lesions have a profound impact on cancer cell migration,
invasion and regulation of the immune system through tumor-extrinsic manipulation of the
microenvironment (4, 5). The importance of the host microenvironment in neoplastic
progression, independent of tumor manipulation, is also underscored by studies demonstrating
that fibroblasts, among many other stromal and immune cell types, stimulate growth of preneoplastic and neoplastic cells along with promoting drug resistance (6-8). Given these
observations, understanding the complex interactions between genomic lesions and tumor
microenvironment in mouse models is crucial to uncovering new anti-cancer therapies. Thus,
implementation of molecular imaging within basic research and pre-clinical mouse models of
cancer has become an essential tool for interrogating these hallmarks of cancer and monitoring
tumor progression within the proper physiologic context.
Currently, the most commonly used types of mouse models of cancer can be grouped into
primary tumor cells, tumor cell lines and their associated tumor engraftments, or geneticallyengineered mouse models (GEMMs) of spontaneous cancer. Xenograft models entail
subcutaneous or orthotopic transplantation of human cell lines or primary tumors into an
immunodeficient mouse while mouse allografts similarly employ orthotopic or subcutaneous
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host implantation. Although traditional cell line xenografts and mouse allografts have yielded
limited clinical correlations (9-11), the robust ability of human ‘xenopatient’ models (12) and
newly adapted “human-in-mouse” (HIM) cancer models for accurately modeling patient disease
and predicting patient response have been encouraging (11, 12, 13). However, due to the inherent
nature of xenograft and HIM models, immune compromised mice are required, and thus the
contribution of the immune system and the autochthonous tumor stroma cannot be fully
interrogated. Additionally, these tumors are implanted as a population of late-stage tumorigenic
cells and do not accurately recapitulate all steps of tumorigenesis. In contrast, GEMMs permit
investigation of the proper tumor microenvironment, model tumor development from the initial
genetic alteration in situ to subsequent neoplastic progression to metastasis, and enable tissuerelevant drug pharmacodynamics (13). Constitutive or conditional GEMMs of cancer
(transgenic, knock-out or knock-in) as well as chimeric or non-germline GEMMs have proven to
be of significant interest for cancer biology research as well as accurate predictive models of
human cancers for pre-clinical drug development (14-16).

Molecular Imaging with Genetically-Encoded Reporters
Regardless of the mouse model, molecular imaging techniques (nuclear, fluorescence,
and bioluminescence) at both macroscopic and microscopic scales make it possible to explore
the consequences of the interactions between tumor cells and microenvironment during tumor
progression in vivo, in real time. This expanding set of molecular probes, detection technologies,
and imaging strategies, collectively termed molecular imaging, now provides researchers and
clinicians alike, new opportunities to visualize gene expression, biochemical reactions, signal
transduction, protein–protein interactions, regulatory pathways, cell trafficking, and drug action
noninvasively and repetitively in their normal physiological context within living organisms in
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vivo (17-21). In particular, integration of genetically-encoded imaging reporters into live cells
and, more importantly, whole animal mouse models of cancer has provided powerful tools to
monitor cancer-associated molecular, biochemical, and cellular pathways in vivo (22).
Traditional means of interrogating these oncogenic-associated biological processes and
characterizing new anti-cancer therapeutics have relied on invasive techniques that are often
laborious and only provide a static window of analysis. Microscopic fluorescence imaging with
green fluorescent protein (GFP) provided pioneering studies of biological activities and cellular
processes at high resolution (23). Concurrently, molecular probes, contrast agents, exploitation
of fundamental tissue characteristics, and development of multi-spectral fluorescent and
bioluminescent (luciferase) proteins and highly sensitive instrumentation, have revolutionized
non-invasive and longitudinal imaging of cancer biology at the whole organism level.
These various imaging modalities and strategies acquire macroscopic information in vivo
through two basic strategies: injected agents or genetically-encoded reporters. Injected agents
have contributed significantly to pre-clinical cancer research and also have great potential for
translation, but require significant optimization and characterization depending on the
experimental model, biological target, background noise, instrumentation, route of
administration, and, for human use, are impacted by similar regulatory hurdles as therapeutic
agents (21, 22). An inherent constraint to the development of conventional injectable agents is
that the details of synthesizing, labeling and validating a new and different ligand for every new
receptor or protein of interest impose long cycle times on development. However, geneticallyencoded reporters offer more modular tools for preclinical research, which once cloned into
appropriate vectors and biologically confirmed, can be quickly applied to a broad array of
applications with minimal modification (22, 24). While genetically-encoded imaging reporters
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are under development for use in humans, the potential for immunogenicity and transduction
inefficiencies raise unique challenges (25). However, genetically-encoded imaging reporters
represent a technically and biologically robust means of monitoring the dynamics of tumor
biology with relatively high temporal resolution and various levels of spatial resolution when
coupled with GEMMs.
Imaging of biological processes using genetically-encoded reporters relies on the ability
of the reporter gene to produce a measureable signal that can be detected and quantified by
extrinsic instrumentation. Reporter expression and thus signal output is controlled by a
regulatory element such as constitutive or conditional DNA-promoter system, or subsequent
peptide fusion that regulates posttranslational modulation of the reporter. Most commonly used
genetically-encoded imaging reporters produce signal through optical imaging strategies, but
magnetic resonance imaging (MRI) and radiopharmaceutical (PET/SPECT) approaches have
been explored. Optical imaging of genetically-encoded reporters can provide image contrast
through, 1) reporter-mediated enzymatic activation of an optically silent substrate (e.g., lightproducing luciferase-based oxidation of D-luciferin in the presence of Mg2+, ATP, and O2) (22,
26), 2) photo-excitation signal production (e.g., fluorescent proteins) (23), or 3) reportermediated enzymatic release/trapping of optically-tuned leaving groups (e.g., β-glucuronidasemediated hydrolysis of glucuronide groups coupled to NIR imaging dyes (27)). Nuclear imaging
of genetically-encoded reporters can utilize, 1) enzyme-mediated modification of a labeled
substrate causing intracellular accumulation or proximal cell association (e.g., HSV1-TKmediated phosphorylation of radiolabelled nucleosides for PET imaging) (28, 29), or 2) direct
import of a labeled tracer (e.g., sodium iodide transporters/ radioiodines for PET/SPECT) (22,
30). An early innovation for MRI was use of a galactopyranose blocking group coupled to a
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gadolinium-based relaxivity agent that rendered the MRI contrast agent sensitive to expression of
the reporter gene β-galactosidase (31).
Genetically-encoded reporters with optical outputs, specifically fluorescence or
bioluminescence, are most commonly used for cancer research in mouse models due to overall
modest cost, sensitivity and lack of technical restrictions and required regulatory barriers often
encountered with other approaches. Whole animal fluorescence imaging in vivo suffers from low
signal-to-noise as a result of background auto-fluorescence, modeling-dependent photon
quantification, photo-bleaching, low tissue penetration and low resolution (26). In addition,
fluorescent proteins are known to generate reactive oxygen species (ROS) that can induce
significant cellular stress under selected conditions (23). However, computed image analysis
along with laser-induced fluorescence has increased the sensitivity of non-invasive fluorescence
imaging in vivo (32). Also, compared to other genetically-encoded reporters, fluorescent proteins
are independent of substrate delivery and pharmacokinetics, are amenable to high resolution
microscopic analysis, and several new far red-shifted fluorescent proteins have been developed
that enhance the penetration of photons in vivo (21).
Bioluminescence imaging has emerged as an invaluable optical imaging tool and has
become widely adapted to molecular imaging of cancer models in vivo. The major advantages of
luciferase reporter systems in vivo include essentially zero background signal, high signal-tonoise imaging, relative ease of signal acquisition, modest cost, user-friendly instrumentation and
direct measure of live cell mass (ATP-dependent activity). Moreover, luciferase enzymes have a
shorter half-life (~3-5 hrs for native North American P. Pyralis firefly luciferase and Renilla
luciferase versus 12-26 hrs for native GFP variants) and are rapidly folded and functional posttranslationally, thereby providing a more robust readout of kinetic processes such as
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transcriptional activation, protein degradation, reversible protein-protein interactions and other
rapid biological processes (22, 33, 34). Also, red-emitting firefly and click beetle luciferases with
relatively higher photon outputs have advanced luciferase imaging beyond the original long
wavelength luciferase variants, providing further advantages over Renilla/ Gaussia luciferases
and related mutants that emit at blue or blue-green wavelengths, which, while perhaps useful,
remain suboptimal for imaging in vivo. However, luciferase enzymes in general are dependent on
substrate pharmacokinetics, and furthermore, the Renilla/ Gaussia substrate (coelenterazine) is
transported by P-glycoprotein and auto-luminesces due to auto-oxidation from serum albumin
(35, 36), which can confound analysis in vivo. Additionally, due to overall low photon output,
luciferase reporters traditionally have been limited to macroscopic imaging analysis. However,
recent advances in low-light microscopy technologies have permitted the interrogation of live
cells and live bioluminescent tissues ex vivo at high magnifications (37-39), a notable advance
that extends the capacity of BLI.
Similar to studies in cultured cells, genetically-encoded bioluminescent reporters in mice
offer the ability to non-invasively monitor transcriptional regulation, post-transcriptional and
post-translational events, as well as transformation and neoplastic progression. When coupled
with an oncogenic protein or signaling pathway of interest, these properties of BLI allow various
features of cancer to be interrogated such as chemoresistance, inflammation, angiogenesis, DNA
maintenance, apoptosis, therapeutic response and oncogene addiction. Additionally, BLI reporter
mice can simultaneously and directly assess tumor burden through constitutive or conditional
expression of luciferase. With the sensitivity of BLI reporter mice, one can also non-invasively
survey and monitor small, non-palpable tumors as well as metastases in a relatively fast and
efficient manner. While a considerable amount of early effort was directed toward fluorescent
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GEMMs of cancer, only more recently have mouse models been advanced with the versatility of
BLI. Thus, the development and utility of BLI in GEMMs of cancer is the focus of this review
and the reader is referred elsewhere for overviews of molecular imaging in non-GEMM models
(19-22, 40). More specifically, this review highlights GEMMs of cancer reported in the last halfdecade that utilize genomically-encoded bioluminescence reporters for investigating tumor
biology and associated signaling pathways inherent to the cancer system or pathway of interest,
summarizes notable models, and suggests future directions for BLI-coupled GEMMs of cancer.
In addition to the models highlighted in detail below, an extensive referenced list of cancerrelated luciferase-coupled GEMMs according to mode of luciferase regulation (Table I) and
cancer type (Table II) are included for the general reader.
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Regulation of Luciferase in GEMMs of Cancer
Transcriptional
Transcriptionally-regulated luciferase enzymes provide a robust tool to monitor tissuespecific tumor burden or interrogate biological processes in tumors in vivo. Transcriptional
systems are simple in design and consist of a composite or endogenous promoter sequence
upstream of luciferase and introduced into the mouse genome either through transgenic or
targeted knock-in approaches. Conventionally, genetic regulatory elements derived from
cytomegalovirus (CMV) or simian vacuolating virus 40 (SV40) provide robust protein or
reporter expression in the cell or tissue harboring the construct. However, at the whole animal
level, to track spontaneous tumor progression, researchers have utilized promoters or cis acting
regulatory regions from endogenous or viral genes activated specifically in neoplastic cells. For
example, prostate growth and development is largely governed by androgen signaling, thus
offering an avenue to specifically image prostate cells in physiological or pathological states.
With this in mind, a plethora of transgenic luciferase mice have been developed utilizing
composite promoters from human kallikrein 2, probasin, prostate-specific antigen and various
forms of concatenated minimal androgen response elements (Table I). Other transgenic models
also use endogenous androgen-responsive promoters derived from rat probasin and human
prostate specific antigen (41, 42). Baseline signal with varying intensities is confined to the
prostate with minimal promoter activity outside of the prostate for most models, allowing noninvasive prostate-specific BLI. Prostate bioluminescent signal from these promoters correlates
with normal prostate development and decreases upon castration or androgen ablation. However,
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in only one transgenic model (Tg(PSA->Luc)) did the reporter mouse demonstrate an increase in
prostate bioluminescence when crossed to a previously characterized TRAMP model that
expresses oncogenic SV40 small and large T antigen in the prostate via a minimal rat probasin
promoter (42). Two other similar prostate transcriptional luciferase reporter models failed to
show a consistent increase in prostate signal when crossed to TRAMP models despite
histologically confirmed tumor progression (43, 44). It was suggested that the inability of these
reporter models to show a tumorigenic increase in prostate bioluminescence, as seen in Tg(PSA>Luc; rPB-Tag) mice, was due to the androgen independence of these aggressive,
neuroendocrine carcinomas that are characteristically observed on a FVB background (45).
However, this observation is unsatisfying given the fact that if the tumors were truly ARindependent, the relatively high prostate-specific signal (>106 photons) would be, by default,
representative of tumor mass only and would have been expected to increase along with the
tumor, which was not observed despite tumor progression (43, 44). These discrepancies point out
the potential pitfalls of using transgenic strategies with regulated promoter-based reporters for
readout of tumor burden which can be confounded by gene locus effects, gene silencing, or
tumor evolution, independent of promoter- or gene-dependent luciferase expression. This
discordance can be investigated by correlating bioluminescence with tumor burden as measured
by an alternative means (caliper measurements, MRI, etc.). Conversely, bioluminescent promoter
systems in transgenic GEMMs of cancer that are intended to interrogate gene-associated
oncogenic processes can ultimately become a measure of tumor burden alone, completely
separate from the original gene-associated biological intent. Thus, care should be taken when
developing a reporter mouse using luciferase (or any reporter gene) to monitor tumor hallmarks
when coupled to a gene of interest.

Transcriptional bioluminescent reporters knocked into an
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endogenous locus or immediately downstream of a start codon also provide a means to monitor
tumor biology and development in vivo with decreased signal variability compared to that often
observed between transgenic founder lines. Although technically more difficult, knock-in
strategies maintain the entire promoter regulatory region adjacent to the luciferase gene and thus,
in principle, provide a more accurate measure of gene transcription within the native context of
the genome. This is exemplified in a p21Waf1/CIP knock-in luciferase model (p21FLuc) in which
firefly luciferase was genetically introduced into the endogenous p21 locus downstream of the
native promoter (Fig. 1A) (37). p21 is a critical regulator of cell cycle progression, is a direct
transcriptional target of p53 among many other signaling pathways and is frequently altered in
human cancers (46). As expected, p53-dependent activation of the p21 promoter in response to
external beam irradiation (IR) could be non-invasively and repetitively monitored over time in
p21FLuc mice (37) using surgically implanted micro-osmotic pumps that constantly delivered Dluciferin substrate (47) (Fig1. B). Previous attempts to non-invasively monitor p21 levels in vivo
utilized transgenic transcriptional luciferase or lacZ reporter mice that were regulated by short
fragments of the p21 promoter (<5 kb) and only produced robust signal when strains harbored
multiple copies of the reporter (up to 23) (48, 49). In the knock-in reporter strain, baseline
bioluminescence levels three logs higher than the luciferase transgenic strain allowed Tinkum et
al. (37) to identify specific organs that contained high levels of p21 independent of p53 status.
Additionally, select organs showed dramatic regional differences in p21-luciferase activity that
was identified using high-resolution bioluminescence microscopy to localize live sub-organ
structures and specific cell populations with high-level expression of p21 (Fig. 1C), providing
new insight into future lines of investigation.
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Similar to organ-specific imaging in the aforementioned prostate transgenic models, subcellular whole animal imaging of tumor burden can be accomplished using transcriptional
reporter mice as well. Scotto et al. (50) introduced a mCherry-Luciferase fusion into the
endogenous CD19 locus. This enabled non-invasive longitudinal imaging and microscopic
analysis ex vivo of the B-cell lineage under normal and pathologic conditions when crossed to a
λ-MYC transgenic mouse model of spontaneous B-cell lymphoma (50). Knock-in strategies
appear to offer more refined imaging of whole organs or distinct cell lineages in terms of
sensitivity and specificity when it comes to analysis of GEMMs of cancer at the macroscopic
scale.
However, a caveat is that knock-in strategies can potentially disrupt expression of the
endogenous locus by usurping its promoter function or preventing expression of the targeted
locus, thereby disrupting the process under investigation. In this regard, several groups have
adapted viral internal ribosome entry sites (IRES) to couple translation of luciferase enzymes to
the transcriptional activation of an upstream gene in a bicistronic fashion while maintaining
expression of the targeted gene. One group utilized this strategy by knocking-in an IRES-EGFPluciferase fusion downstream of the endogenous vascular endothelial growth factor receptor 3
stop codon (Vegfr3EGFPluc) (Fig. 2A) (51). VEGFR3 is a potent regulator of angiogenesis,
lymphangiogenesis and metastasis and is emerging as an alternative target in combination with
other VEGF anticancer therapeutics (52-54). The authors used this reporter mouse to quantify the
association between inflammation and lymphangiogenesis during wound healing and in response
to a contact hypersensitivity inflammation model. Microscopic analysis of the coupled EGFP
reporter allowed the authors to show that Vegfr3EGFPluc luciferase intensity correlated with
increased lymphatic network density. Additionally, tumor-activated lymphangiogenesis was
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observed in DMBA/TPA-skin papillomas and at lymph nodes distant from subcutaneous
injection of B16-V5 melanoma cells (Fig. 2B-C). Importantly, the sensitivity and longitudinal
capability of luciferase imaging permitted identification of tumor-activated lymphangiogenesis at
distant lymph nodes that preceded tumor metastasis (Fig. 2C).

Post-Transcriptional
The luciferase enzyme can also be coupled to post-transcriptional mechanisms that
monitor mRNA modifications associated with oncogenic signaling. This can be accomplished by
coupling or fusing a luciferase enzyme to a coding sequence such that modification or interaction
of the mRNA or protein results in modulation of luciferase signal. This strategy was applied to
investigate the effect of the tumor microenvironment on tumor unfolded protein response (UPR)
and endoplasmic reticulum (ER) stress in live animals by visualizing alternative splicing (55).
The heterogeneous tumor microenvironment imposes ER stress upon the tumor through hypoxia,
acidic pH and low nutrients (56). These constraints, along with deregulated translation and
proteotoxicity place evolutionary pressure on developing cancer cells, which can respond by
augmenting several key steps of the UPR pathway for survival. Thus, UPR is an emerging target
for anti-cancer therapies (56). Upon loss of ER homeostasis, activation of inositol-requiring 1α
(IRE1α), one of the three UPR pathways, results in unconventional splicing of a 26 bp intron
from IRE1α-X-box binding protein 1 (XBP-1), thereby incorporating an extended open reading
frame that increases protein stability and augments XBP-1 transcriptional activation of essential
UPR response genes (57, 58). Spiotto et al. (55) created a transgenic mouse that harbors a CMV>XBP1-Luc transgene which is regulated in a manner similar to that of the endogenous XBP1
and thus, luciferase expression is a direct readout of this splicing event (55). Under normal
physiological conditions, the reporter mouse maintained background photonic levels, but
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appropriately displayed tumor-specific signal once crossed to breast cancer models such as,
Tg(MMTV-TAg) and Tg(MMTV-Her2), that localized with ER stress markers upon microscopic
analysis of tumors. Importantly, the authors observed no correlation between tumor size and
bioluminescent signal suggesting XBP1-Luc was a measure of the tumor-intrinsic ER stress and
not overall tumor load. Tumors arising within the same mouse possessed variable signal
intensities, which portrayed the heterogeneic nature of tumor metabolism as further indicated by
differential glucose uptake and hypoxia, and the contribution of the unique tumor
microenvironments within the same mouse. These observations serve as an example of the
sensitivity of BLI compared to other optical imaging modalities that were employed in a similar
transgenic Tg(XBP1-GFP) mouse, which had very low signal that at the time only allowed
endpoint analysis of XBP1 activation in a few extracted organs (59).

Post-Translational
Cancer-associated post-translational modifications and the subsequent effects on protein
processing and protein-protein interactions are amenable to luciferase reporter mice and BLI in
general. Previous designs and biologically affirmed reporters have transitioned from cell culture
to provide the framework for whole animal preclinical evaluation of anti-cancer drugs in the
proper physiological context. Interrogation of inhibitors of the hypoxia inducible transcription
factor 1α (HIF-1α) have been aided by the development and application of various transgenic
mouse models that fused the oxygen-dependent degradation domain of HIF-1α to firefly
luciferase (Tg(ODD-Luc) and Tg(Hypoxic RE->ODD-Luc)) (60-62). Under normoxic
conditions, endogenous HIF-1α protein is retained at low levels due to hydroxylation,
polyubiquitination and subsequent proteasomal degradation and correspondingly, luciferase
background signal levels are low in these luciferase reporter mice during normoxia (63). During
94#
#

hypoxia or hydroxylase inhibition, HIF-1α is stabilized and appropriately, bioluminescence
intensity of these reporter mice increases as a result, thereby indirectly monitoring HIF-1αdependent responses to acute or chronic hypoxia. When crossed to spontaneous Tg(MMTVneu);Beclin1+/fl or carcinogen susceptible RasH2 cancer models, increased bioluminescence was
detected in hypoxic tumors, highlighting the ability to monitor both tumor growth and tumor
hypoxia non-invasively with this reporter mouse (60, 62). Additionally, inclusion of cis acting
hypoxia response elements before a minimal CMV promoter in the Tg(HRE->ODD-Luc) mice
inherently provided interrogation of the transcriptional phase of the HIF-1α positive feedback
loop, which attempts to recapitulate HIF-1α-dependent transcriptional activation of its own
mRNA (62).
The analysis of druggable oncogenic protein-protein interactions can also be interrogated
non-invasively using luciferase reporter mice. This notion is exemplified in a proof-of-principle
mouse model utilizing the Gal4-VP16 “two hybrid” interaction system in which nuclear
interaction of the DNA binding domain of the yeast transcription factor Gal4 with the
transactivation domain from herpes simplex virus VP16 protein can functionally lead to the
transcriptional activation of a Gal4 responsive reporter gene (64). If each component is
individually fused to a set of proteins known to interact, visualization of their proximity and
interaction can be indirectly assessed through Gal4-responsive reporter activation. Pichler et al.
(64) generated a transgenic mouse harboring a luciferase reporter regulated by Gal4 response
elements which could indirectly monitor protein-protein interactions by hydrodynamic somatic
gene transfer of constructs expressing Gal4 fused to p53 and VP16 fused to the SV40 large T
antigen. Using this reporter mouse, abrogation of p53-TAg interaction due to loss of p53 was
readily observed in mice upon shRNA-mediated knockdown of p53 in vivo. Adapting this
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modular system to other models of protein interactions could aid in the preclinical evaluation of
modulators of oncogenic protein-protein interactions longitudinally in whole animals (65).

Conditional Transformation
Exquisite genetic techniques have enabled researchers to initiate and follow
transformation, progression, invasion, metastasis, therapeutic response and oncogene dependence
in spontaneous or conditional GEMMs of cancer. Luciferase reporter mice can be genetically
coupled to these molecular and biological events, thus permitting longitudinal and non-invasive
imaging of a relatively small cohort of mice that can provide statistically meaningful results
since each animal serves as its own control. In one example, inactivation of the retinoblastoma
(RB) tumor suppressor pathway in response to platelet-derived growth factor (PDGF)-induced
oligodendrogliomas was indirectly monitored through activation of a E2F1 promoter driving
luciferase in an engineered transgenic reporter mouse (66, 67). Direct monitoring of genetic
deletion of tumor suppressors or activation of oncogenes is also possible through the use of
several floxed firefly luciferase transgenic mice in which Cre-mediated excision of an upstream
floxed-stop cassette allows downstream luciferase expression. Previously, Lyons et al. generated
a transgenic strain in which the beta actin promoter-driven luciferase expression is regulated by
removal of a floxed GFP-polyA transgene (68). Crossing the reporter strain with a floxed
Kras2v12 followed by adeno-Cre inhalation induced lung adenocarcinomas that could be
simultaneously monitored using BLI for over 100 days. Using the same reporter mouse crossed
to a conditional prostate-specific Cre-expressing strain, Tg(PB-Cre4);Ptenfl/fl, another group was
able to monitor for over 400 days spontaneous prostate adenocarcinoma initiation, progression,
response to castration and subsequent development of castration-resistant prostate cancers
(CRPC) reliably in a small cohort of animals (69). The emergence of CRPC was not observed
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and potentially may never be observed through coupled-reporter gene imaging in the androgendependent transcriptional prostate carcinoma reporter models discussed earlier. This highlights
the utility of Cre/loxP approaches, which can mark tumor cell lineage prior to biologic-specific
functions, thereby improving upon the complexities of transcriptional reporters, such as the
prostate cancer reporter mice discussed above. The authors observed that the non-recombined βactin promoter-driven reporter was leaky and read-through could be observed in muscle tissue
using reverse transcriptase PCR of tissue mRNA. This was potentially due to the strength of this
promoter in regions of high actin expression and/or from the variability associated with the loci
or extent of genomic integration of the reporter. Also, the authors observed pronounced
luciferase signal at intraperitoneal sites of repeated luciferin injection, which could be remedied
through tail vein injection of the luciferase substrate. Svensson et al. also utilized a conditional
Rosa-Luc knock-in reporter mouse to monitor prostate carcinoma progression on the less
aggressive C57BL/6 background (70), using the same strategy as Liao et al. (Tg(PBCre4);Ptenfl/fl) (71). Despite the now well-characterized differences in prostate development due
to the genetic backgrounds of the mouse used (e.g., C57BL/6 versus aggressive FVB/N),
Svensson et al. noted a dramatic reduction in luciferase signal variability over time compared to
Liao et al. These differences potentially stem from the Rosa26 locus and/ or the fact that the
Rosa-Luc mouse was strategically backcrossed onto an albino C57BL/6 background, thereby
greatly reducing signal attenuation due to coat color. Additionally, analysis of Tg(PBCre4);Ptenfl/fl prostate tumors indicated the BLI was a more accurate readout of prostate tumor
burden because ex vivo analysis revealed massive fluid retention in the anterior prostate that
could be misinterpreted as tumor mass when analyzed via MRI.
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Cre/LoxP-luciferase reporter mice have also been used for following stochastic neoplastic
genetic lesions and marking distinct cell lineages when coupled to other fluorescent or LacZ
reporter strains. Liu et al. implemented this strategy to identify organ susceptibility and monitor
subsequent tumor progression in a sophisticated whole animal Notch1 loss-of-heterozygosity
(LOH) model crossed to a floxed stop cassette-Rosa26-click beetle red luciferase (Rosa->CBR)
knock-in reporter mouse (Fig. 3) (72). The authors generated a mouse harboring a knock-in nonfunctioning Notch1-Cre fusion on one allele along with a conditional Notch1 knockout cassette
on the second allele (Notch1fl), which was further crossed with either the conditional Rosa->CBR
mouse or other conditional Rosa->LacZ and Rosa->EYFP reporter mice strains (Fig. 3A).
Following the first round of embryogenic Notch1 expression, any second endogenous liganddependent activation of Notch signaling in Notch1-Cre;Notch1fl mice results in cleavage and
subsequent nuclear translocation of the Notch-intracellular-domain (NCID)-Cre fusion, which in
turn results in excision of the remaining floxed Notch1 allele throughout all active Notch1signaling cells (Fig. 3A). Thus, stochastic LOH and the subsequent development of highly
vascularized tumors could be indirectly monitored at the macroscopic (Rosa->CBR) and at the
cell lineage level (Rosa->LacZ/EYFP) by Cre-mediated excision of the co-engineered lox-stoplox cassette inserted upstream of the Rosa locus on each allele in these reporter mice (Fig. 3B,
C). The Rosa->CBR mouse has since been crossed with the Rosa->LacZ mouse to create a
conditional Rosa->CBR/ LacZ dual-modality reporter mouse that has been extensively
backcrossed onto the albino C57BL/6 background (Piwnica-Worms, D. et al. unpublished). This
dual reporter mouse has the potential to provide a robust and powerful readout of Cre-activation
and carcinogenesis through the high, red-emitting photonic output of CBR and the microscopic
utility of LacZ staining.
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Tet-Regulated Systems
Conditional cancer mouse models using genetically-coupled luciferase reporters can also
utilize tetracycline (or the more stable analogue, doxycycline)-regulated expression systems or
tamoxifen-inducible systems for spatial and temporal induction and reversion of oncogene
biology in mice. However, tetracylcine (tet)-systems are more commonly used due to toxicities
associated with tamoxifen and the Cre-estrogen receptor fusion observed in tamoxifen-inducible
mice (73, 74). In the tet-on system, expression is dependent on binding of a reverse tetracyclineregulated transactivator (rtTA) to the tetracycline-response promoter elements in the tet-operator
(tet-o) engineered upstream of the coding sequence of interest in the presence of tetracycline
(75). The tet-off system uses a different tetracycline-regulated transactivator protein (tTA) which
cannot bind tet-o in the presence of tetracycline, effectively silencing expression only when
tetracycline is present (75-77). Regardless of the system, expression of the tetracycline
transactivator (and hence the gene of interest) can be regulated through promoters specific to a
tissue or cell type of interest. Ultimately, these systems have been instrumental in determining
the extent of oncogene dependence in spontaneous mouse tumor models within the proper
context in vivo. Additionally, conditional repression of an oncogene mimics therapeutic
inhibition in a targeted molecular pathway and coupled luciferase reporters allow longitudinal
imaging confirmation of this ‘therapeutic inhibition’. In one example, Du et al. generated a
conditional tet-o-polyoma middle T antigen (PyMT)-IRES-luciferase reporter mouse, Tg(tet-oPyMT-IRES-Luc), to investigate the cell-specific effect of oncogene induction on the
development and progression of pancreatic cancer using two previously reported conditional Tetsystem mice Tg(Rip7-rtTA and Pdx1-tTA) (78). Within 1 day of doxycycline removal, noninvasive BLI imaging allowed confirmation of subsequent oncogene withdrawal in Tg(Rip799#
#

rtTA; tet-o-PyMT-IRES-Luc) mice. Interestingly, this had no effect on the established
hyperplastic β cell islets, indicating oncogene independence, which was also conversely
confirmed using the Pdx1-tTA mice. Additionally, 10% of Tg(Pdx1-tTA; tet-o-PyMT-IRES-Luc)
mice developed aggressive acinar cell carcinomas as a result of activation of the Pdx1 promoter
in early pancreatic progenitor cells. Regression of these tumors when deprived of PyMT,
confirmed as soon as 1 day after doxycycline addition by BLI, indicated a requirement or
dependence on PyMT for sustained tumor maintenance. Another group generated a tet-off
luciferase reporter mouse to delineate the requirement of MYCN in medulloblastoma (79). One
of the two lines crossed to generate this bigenic mouse contained the cerebellum-specific
glutamate transporter1 (Glt1) promoter driving expression of tTA and the other a tet-o-driven
bidirectional MYCN and firefly luciferase expression cassette. Using a characterized amount of
photon flux as a measure of tumor burden, the authors repressed MYCN expression in a subset
of mice by feeding them doxycycline-containing chow. Within one week, they observed a
dramatic drop in bioluminescence and tumor regression, confirming the requirement for
sustained MYCN expression in these tumors and suggesting its potential for targeted therapy in
medulloblastomas. Thus, bioluminescent reporter mice coupled to integrated conditional tetregulated systems are invaluable tools to quickly and efficiently monitor oncogene expression in
manageable cohorts of mice and validate potential therapeutic targets, which guide and inform
more invasive and laborious secondary tumor analyses.

Lessons Learned and Future Considerations
As with all experiments, meticulous planning and a dose of foresight are paramount to
the success of engineering a genetically-encoded luciferase mouse. There are several
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considerations and nuances that can dramatically reduce time and labor and expand upon the
potential of a reporter mouse in terms of signal sensitivity, biological accuracy and overall
utility. As the genetic background of the mouse strain can dramatically affect the biology of the
cancer, for example, as seen in the differential sensitivity of C57BL/6 and FVB strains to
prostate cancer models as well as other models (80), so will genetic background inherently
modulate the signal strength and interpretation of coupled luciferase reporters. When possible, an
albino mouse strain should be used to minimize signal attenuation. This will allow for enhanced
sensitivity for gross analysis of luciferase expression, and will strongly benefit low luciferaseexpressing tissues in scenarios such as low endogenous expression, metastasis or tumor
regression. Commercial albino C57BL/6 embryonic stem cells are now available that have high
germline rates, and are technically amenable to genomic manipulation for targeted or transgenic
reporter approaches, thereby minimizing onerous backcrossing. When specifically attempting to
monitor live tumor cells, a relevant genetically-encoded reporter should be specific to live cell
mass alone and will likely be most accurate when using Cre/loxP-based or knock-in strategies as
discussed previously. Although technically much simpler, transgenic transcriptional reporters
can be overridden by tumor evolution or genomic loci effects as seen in the androgen-sensitivity
GEMMs of prostate cancer discussed above. Low light microscopy, which is capable of imaging
live luminescent tissues, is becoming accessible to the general researcher and is approaching the
high levels of magnification and resolution necessary for subcellular inspection. Nonetheless,
analysis ex vivo of live tissues and organs synergizes with the whole animal imaging capabilities
of luciferase reporter mice and also can be performed using luciferase antibodies or secondary
coupled reporters such as fluorescent proteins as used to observe lymphatic vessels in
Vegfr3EGFPluc mice (51).
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Conclusions
Genetically-encoded luciferase reporter mice have made a profound impact on imaging
tumorigenesis, cancer progression, response to therapies and the contributions of the tumor
microenvironment when crossed with GEMMs of cancer. Compared to other imaging modalities,
bioluminescence provides an efficient, relatively low cost, non-invasive and longitudinal means
to investigate genetic alterations in the autochthonous tumor environment and its ultimate effect
on tumor biology. Combining the advantages of genetically-encoded luciferase reporters with the
development of new and clinically accurate GEMMs of cancer paints a bright horizon for our
understanding of molecular cancer biology and the development of novel and durable anti-cancer
therapies.
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A.3 Figures
A
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Figure 1. Whole animal imaging of p21 promoter activity. (A) Schematic representation of
p21FLuc reporter mice with luciferase knocked into the endogenous p21 locus. (B) Non-invasive,
whole animal imaging of p53-dependent p21 promoter activity in response to radiation in
p21+/FLucTrp53+/+ and p21+/FLucTrp53fl/fl mice. (C) Low-light, bioluminescence microscopy of
p21 promoter activity in various p21+/FLuc live tissues, including the villi from the small intestine,
throughout the liver, in the epithelial cell layer below the keratinized penile spines, as well as the
epithelial cell layer of the vagina. Bars, 200 µm; 50 µm for the penis. Images were modified and
reprinted with permission from Molecular and Cellular Biology.
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Figure 2. Imaging inflammation and tumor-associated lymphangiogenesis. (A) Schematic
representation of the Vegfr3EGFPluc reporter knocked in downstream of the endogenous Vegfr3
locus, which utilizes an internal ribosome entry site (IRES) for monitoring Vegfr3 expression.
(B) DMBA/TPA-induced skin papillomas in Vegfr3EGFPluc/+ reporter mice displayed localized
lymphangiogenesis as indicated by the black arrows. (C) Whole body imaging of tumoractivated lymphangiogenesis over time in a B16-V5 melanoma xenograft model at distant lymph
nodes (red arrows) prior to metastasis of the primary tumor xenograft in female Vegfr3EGFPluc/+
reporter mice. Images modified and reprinted with permission from Proceedings of the National
Academy of Sciences.
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Figure 3. Imaging whole animal Notch1 loss-of-heterozygosity (LOH) and surveying subsequent
tumor development. (A) Schematic representation of Notch1-Cre;Notchfl; Rosa->CBR cells prior
to Notch1 ligand activation. (B) Upon activation, cleavage of NOTCH1 (between S2 and S3)
permits translocation of the Notch-intracellular-domain (NCID)-Cre fusion into the nucleus
where it excises both the remaining wildtype Notch1fl allele, and the floxed stop cassette
preceding CBR. Through these series of Cre-mediated excisions, lineage tracking of Notch1
LOH can be longitudinally imaged via the genetically-coupled floxed Rosa->CBR reporter. (C)
Whole animal imaging of the development and progression of Notch1 LOH-induced
angiosarcomas of the liver as imaged in Notch1+ or Notch1fl mice crossed to Notch1-Cre;Rosa>CBR reporter mice. Images modified and reprinted with permission from Journal of Clinical
Investigation.
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Table I. Cancer-Associated Processes Observable in Genetically-Encoded Luciferase Reporter Mice.
Mode of Regulation

Cancer Biology Target

Genetic Strategy

Ref.

Cell cycle
B-cell specific imaging
Various
Various
Chemoresistance
Lymphangiogenesis
Apoptosis
Telomerase regulation
Angiogenesis
Angiogenesis
Angiogenesis
Various
Various
Cre mediated Rb inactivation in pituatary gland.
PDGF induced inactivation of Rb pathway
PDGF-induced activation of Gli1/2
Prostate specific imaging
Systemic response to anti-androgen therapy
Afp activation in DEN induced HCC
Afp activation in DEN induced HCC
Androgen deprivation in normal prostate, TAg, and JOCK models
Androgen deprivation in normal prostate, TAg, and JOCK models
Androgen deprivation in normal prostate and TAg model
Androgen deprivation in normal prostate and TAg model
Δ16Her2 induced mammary gland dysplasia
SV40 ER induced pancreatic cancer monitoring
Estrogen receptor activation

KI(p21 promoter->Luc)
KI(CD19 promoter->Luc)
KI(Cox-2 promoter->Luc)
Tg(Egr1 promoter-> Luc)
KI(Mdr1a promoter->Luc)
KI(IRES-EGFP-Luc downstream of Vegfr3)
Tg(Birc5 promoter-> Luc)
Tg(hTERT BAC->Rluc)
Tg(Vegf promoter->TSTA-Luc)
Tg(Vegfa promoter->EGFP-Luc)
Tg(Vegfr2 promoter->Luc)
Tg(NF-κB RE-> Luc)
Tg(Smad 2/3 RE-> Luc)
Tg(Pomc promoter-> Luc)
Tg(E2f1 promoter->Luc)
Tg(Gli1/2 responsive promoter->Luc)
Tg(Pbsn promoter + androgen response elements->Luc)
Tg(Slp-androgen response elements -TK->Luc)
KI(Afp promoter->TK-IRES-Luc)
Tg(Afp promoter -> Luc)
Tg(syn. Pbsn promoter-> Luc)
Tg(syn. Psa promoter -> Luc)
Tg(Psa promoter-> Luc)
Tg(Psa promoter-> Luc)
Tg(MMTV-Δ16Her2-IRES-Luc)
Tg(Rip1 promoter->SV40 ER-IRES-Luc)
Tg(Estrogen RE->Luc)

(37)
(50)
(81)
(82)
(83)
(51)
(84)
(85)
(86)
(87)
(88)
(89)
(90)
(91)
(67)
(92)
(41)
(93)
(94)
(95)
(43)
(43)
(42)
(44)
(96)
(97)
(98)

ER Stress

Tg(CMV->XBP1-STOP-SA-Luc)

(55)

Hypoxia
Hypoxia
Hypoxia, Neu/ Beclin1+/fl induced mammary gland dysplasia

Tg(Hypoxic RE->ODD-Luc)
KI(Rosa26 promoter->ODD-Luc)
Tg(MMTV->neu; ODD-Luc); Beclin1fl/+

(62)
(61)
(60)

Modular nuclear protein-protein interactions

Tg(Gal4 promoter-> Luc)

(64)

Transcriptional

Post-Transcriptional

Post-Translational

Protein-Protein Interactions
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Transformation
Cre-Activation
Cre Recombination
Cre Recombination
Cre Recombination
Cre Recombination

Tg(Pomc promoter->Cre; Pomc promoter->Luc)
Tg(β-actin promoter->flx-GFP-pA-flx-Luc-pA)
KI(Rosa26 promoter ->flx-STOP-flx-Luc)
Tg(CAG promoter->flx-STOP-pA-flx-TAg-Luc)

(91)
(68), (71)
(99), (70)
(100)

Cre Recombination

KI(Notch1
promoter ->Notch1-Cre;->Notch1flx; Rosa26 promoter->flx-STOP-flx-CBR)

(72)

Coupled to MYCN expression
TBX3 induced mammary gland dysplasia
Wnt1 induced mammary adenocarcinoma
PyMT induced pancreatic cancer monitoring
PyMT induced pancreatic cancer monitoring
HPV16 E7 induced cervical cancer

Tg(Glt1 promoter->tTA; tet-o-Mycn-Luc)
Tg(MMTV->rtTA; tet-o-myc-Tbx3-IRES-Luc)
Tg(MMTV->rtTA; tet-o-Wnt1-IRES-Luc)
Tg(Pdx1-rtTA; tet-o-PyMT-IRES-Luc)
Tg(Rip7 promoter->tTA; tet-o-PyMT-IRES-Luc)
Tg(Krt5 promoter->rtTA; tet-o-Luc- E7)

(79)
(101)
(102)
(78)
(78)
(103)

Tet-Regulated

Legend:
Tg = transgenic mouse; KI= knock-in mouse; -> indicates promoter driving gene expression; RE = response elements multiple; TK= thymidine
kinase; gene loci are separated by a semicolon (;).
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Table II. Luciferase-Coupled Reporter Mice Utilized in GEMMs of Cancer.
#
Cancer Type

Reporter Regulation

Target Gene/ Process Investigated

Reporter Strategy

Ref.

Transcriptional
Transcriptional
Transcriptional
Translational

Rb inactivation and tumor development in pituitary gland
PDGF inactivation of Rb pathway
PDGF activation of Gli1/2 and gliomagenesis

MYCN driven medulloblastoma

Tg(Pomc promoter-> Luc)
Tg(E2f1 promoter->Luc0
Tg(Gli1/2 responsive promoter-> Luc)
Tg(Glt1 promoter->tTA; tet-o-Mycn-Luc)

(91)
(67)
(92)
(79)

Transcriptional
Transcriptional
Transcriptional
Transcriptional
Transcriptional
Cre Recombination
Cre Recombination
Transcriptional

Androgen deprivation in normal prostate, TAg, and JOCK models
Androgen deprivation in normal prostate, TAg, and JOCK models
Androgen deprivation in normal prostate
Androgen deprivation in normal prostate and TAg model
Androgen deprivation in normal prostate and TAg model
Conditional Pten loss
Conditional Pten loss
Systemic response to anti-androgen therapy

Tg(Pbsn promoter-> Luc)
Tg(Psa promoter -> Luc)
Tg(Pbsn promoter + androgen response elements->Luc)
Tg(Psa promoter-> Luc)
Tg(Psa promoter-> Luc)
Tg(β-actin promoter->flx-GFP-pA-flx Luc-pA)
KI(Rosa26 promoter->flx-STOP-flx-Luc)
Tg(Slp-androgen response elements -TK->Luc)

(43)
(43)
(41)
(42)
(44)
(71)
(70)
(93)

Transcriptional
Transcriptional

Afp activation in DEN induced HCC
Afp activation in DEN induced HCC

KI(Afp promoter->TK-IRES-Luc)
Tg(Afp promoter -> Luc)

(94)
(95)

Tet-on
Transcriptional
Transcriptional
Tet-on

TBX3 induced mammary gland dysplasia
Δ16Her2 induced mammary gland dysplasia
Neu, Beclin+/- induced mammary gland dysplasia
Wnt1 induced mammary adenocarcinoma

Tg(MMTV->rtTA/; tet-o-myc-TBX3-IRES-Luc)
Tg(MMTV->Δ16Her2-IRES-Luc)
KI(Rosa26 promoter ->ODD-Luc)
Tg(MMTV->rtTA; tet-o-Wnt1-IRES-Luc)

(101)
(96)
(60)
(102)

Tet-on
Tet-off
Transcriptional

PyMT induced pancreatic cancer monitoring
PyMT induced pancreatic cancer monitoring
SV40 ER induced pancreatic cancer monitoring

Tg(Pdx1-rtTA; tet-o-PyMT-IRES-Luc)
Tg(Rip7 promoter->tTA; tet-o-PyMT-IRES-Luc)
Tg(Rip7 promoter->SV40 ER-IRES-Luc)

(78)
(78)
(97)

Transcriptional

Krasv12 induced lung tumorigenesis

Tg(β-actin promoter->flx-GFP-pA-flx-Luc-pA)

(68)

Transcriptional

B-cell lymphoma

KI(CD19 promoter->Luc)

(50)

Brain

Prostate

Liver

Breast

Pancreas

Lung

Lymphoma
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Cervical
Tet-off

HPV16 E7 induced cervical cancer

Tg(Krt5 promoter->tTA; tet-o-Luc- E7)

(103)

Transcriptional

Ubiquitous TAg induced tumorigenesis

Tg(CAG promoter->flx-STOP-pA-flx-TAg-Luc)

(100)

Whole animal stochastic Notch1 loss of heterozygosity

KI(Notch1
promoter ->Notch1-Cre;->Notch1flx; Rosa26 promoter->flxSTOP-flx-CBR)

(72)

Spontaneous

Cre Recombination

Legend:
Tg = transgenic mouse; KI= knock-in mouse; -> indicates promoter driving gene expression; RE = response elements multiple; TK= thymidine
kinase; gene loci are separated by a semicolon (;).
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Appendix B: DEVELOPMENT OF TUMORMICROENVIRONMENT ACTIVATED ANTI-CANCER
SALMONELLA
B.1 Contribution to authorship
As second author on the following published manuscript, I performed in vitro and in vivo
anti-tumor experiments and analyzed relevant data in addition to writing the complete
introduction, discussion and respective results and methods sections. Specifically, I personally
cloned P1786-Stx2 anti-tumor vector and performed the in vitro toxicity experiments where in
HeLa cells were incubated with conditioned media extracted from HeLa cells co-cultured with
various genetically engineered Salmonella strains (Figure 5). I also prepared the tumor cells, and
bacteria for the in vivo bioluminescence imaging of the anti-tumor efficacy of P1787-Stx2 in
addition to extracting and preparing the tumor for IHC as well as all data analysis (Figure 6).

B.2 Published manuscript
Flentie, K., Kocher, B., Gammon, S., Novack, D., McKinney, J. & Piwnica-Worms, D. A
Bioluminescent Transposon Reporter-Trap Identifies Tumor-Specific MicroenvironmentInduced Promoters in Salmonella for Conditional Bacterial-Based Tumor Therapy. Cancer
Discovery. 2012 Jul; 2(7):624-37.
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Abstract
Salmonella specifically localize to malignant tumors in vivo, a trait potentially exploitable
as a delivery system for cancer therapeutics. To characterize mechanisms and genetic responses
of Salmonella during interaction with living neoplastic cells, we custom designed a promoterless
transposon reporter containing bacterial luciferase. Analysis of a library containing 7,400
independent Salmonella transposon insertion mutants in co-culture with melanoma or colon
carcinoma cells identified five bacterial genes specifically activated by cancer cells: adiY, yohJ,
STM1787, STM1791, and STM1793. Experiments linked acidic pH, a common characteristic of
the tumor microenvironment, to a strong, specific and reversible stimulus for activation of these
Salmonella genes in vitro and in vivo. Indeed, a Salmonella reporter strain encoding a luciferase
transgene regulated by the STM1787 promoter, which contains a tusp motif, showed tumorinduced bioluminescence in vivo. Furthermore, Salmonella expressing Shiga toxin from the
STM1787 promoter provided potent and selective anti-tumor activity in vitro and in vivo,
demonstrating the potential for a conditional bacterial-based tumor-specific therapeutic.

Statement of significance
Salmonella, which often encounter acidic environments during classical host infection,
may co-opt evolutionarily conserved pathways for tumor colonization in response to the acidic
tumor microenvironment. We identified specific promoter sequences that provide a platform for
targeted Salmonella-based tumor therapy in vivo.
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Introduction
The evolving and highly heterogeneous landscape of tumor genetics and the tumor
microenvironment pose a significant challenge for treating advanced solid tumors (1). Many
characteristics of the tumor microenvironment, such as hypoxia, acidic pH, and a disorganized
vascular architecture, limit delivery and efficacy of therapeutics and radiation treatments (2).
Additionally, tumors undergoing targeted molecular therapy often relapse due to the utilization
of autonomous parallel-redundant signaling pathways (3). Beyond the primary tumor, identifying
disseminated disease that has metastasized to various organ sites is challenging, and systemically
treating cancer often produces off-target toxicities. The ultimate anti-tumor therapy is one that
overcomes these physiologic obstacles while simultaneously targeting tumors and avoiding
normal tissue toxicity.
The remarkable ability of commensal and pathogenic bacterial strains to localize and
preferentially grow within tumors has been well documented (4). The immune-privileged,
hypoxic and nutrient-rich ‘tumor soil’ facilitates colonization by facultative anaerobic bacteria
(5). These observations have spurred research into the diagnostic and therapeutic potential of
genetically engineered and attenuated therapeutic strains of bacteria such as Salmonella, Listeria
and Clostridium (5). Salmonella is one of the most studied of therapeutic bacteria, and upon
systemic administration, is able to colonize xenograft tumors at rates 1,000 times greater than
that of other organs, thereby abrogating tumor growth (6, 7). A firm understanding of the genetic
programs involved in normal pathogenesis, characterization of spatiotemporal kinetics and
dynamics during intra-tumoral colonization in vivo, genetic tractability, as well as the oncolytic
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capacity of Salmonella typhimurium have made Salmonella strains ideal candidates for anticancer bacterial development (8).
S. typhimurium by itself can illicit an anti-tumoral response through several potentially
separate but synergistic mechanisms. First, as a pathogenic and cytotoxic bacterium, S.
typhimurium can induce apoptosis of cancer cells (9). Second, pathogen-associated molecular
patterns (PAMPs) of S. typhimurium, such as lipopolysaccharide (LPS) and flagellin, are capable
of activating innate immunity by initiating pro-inflammatory TLR-MyD88/ TRIF-NF-κB
signaling cascades (10). Third, intracellular Salmonella flagellin can also enhance an anti-tumor
adaptive immune response caused by the associative recognition with cancer cell antigen. The
resulting signaling cascades ultimately augment antigen presentation by dendritic cells (DC),
thereby promoting T cell clonal expansion and differentiation, which leads to an associative
recognition of the cancer cell with the PAMPs of Salmonella (11, 12). Finally, despite the initial
tumor regression, these tumors may eventually relapse, which has spurred the development of
Salmonella as a delivery vehicle for anti-cancer co-therapies (13). Indeed, Salmonella have been
used as tumor-specific vectors for gene transfer of RNAi or suicide genes, as well as targeted
expression of apoptosis-inducing biologics, such as TRAIL, FASL and the bacterial toxin,
Cytolysin A, all of which display pronounced anti-tumor affects in vivo (5).
However, few studies have investigated the specific genetic responses of Salmonella to
tumor cells and bacterial mechanisms regulating these atypical “host” interactions. To address
these quires, we engineered a bioluminescent transposon reporter-trap to screen a S. typhimurium
library for genes specifically regulated by co-culture with malignant cells in vitro. Five genes
were identified by the screen and their promoter sequences were found to be specifically
activated by the acidic microenvironment associated with cancer cells in vitro and tumors in
124

vivo. Finally, we utilized the most pH-sensitive promoter sequence to demonstrate the utility of
tumor-regulated Salmonella promoters to conditionally regulate the expression of a toxic tumor
transgene in vitro and in vivo.

Results
A high-throughput screen to identify tumor cell-induced gene activation
events in Salmonella.
To conduct a large-scale, unbiased screen for genes up-regulated by contact with
malignant cells, we used a Tn5-based promoterless transposon as the backbone of a luxAB
reporter construct. We chose to use the bacterial luciferase enzyme genes (luxAB) only, in
contrast to the full bacterial luciferase operon (luxCDABE), because the size of the transposon
containing the full operon prohibited efficient chromosomal integration, while using only the
luxAB genes allowed for efficient genomic insertion of the transposon. The transposon was
designed to restrict reporter gene expression to only those chromosomal integration sites
downstream of an active promoter. A kanamycin resistance cassette with a constitutive promoter
was also included to select for integration into the chromosome (Figure 1A). After construction,
the purified transposon was electroporated into S. typhimurium strain SB300A1 (14) for random
chromosomal integration, producing a 7,400 clone bacterial library.
Initially, the entire Salmonella library was subjected to a primary screen in the context of
three conditions: tissue culture media alone, B16F10 melanoma cells and HCT116 colon
carcinoma cells, both of the latter in monolayer co-culture with the Salmonella reporter library.
The tumor cells were grown in 96-well plate format overnight and then bacterial clones added to
wells corresponding to each of the two co-culture conditions and media alone. After a two-hour
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incubation, bioluminescence imaging of plates enabled identification of clones specifically upregulating genes in the context of exposure to melanoma and/or colon carcinoma cells (Figure
1A). Results of the screen from co-culture with melanoma and colon carcinoma cells are shown
in Figures 1B and 1C, respectively. In each case, data are shown as a rank-ordered S-plot of the
log2 of the normalized signal for each clone of the library, where normalized signal was the ratio
of the signal in the condition of interest to the signal in media alone. The majority of data points
clustered around zero, indicating that most mutants interrogated in the assay did not show tumorspecific gene regulation. However, quartile analysis with a boundary for hit selection
corresponding to a high stringency targeted error rate (α = 0.0027) identified five candidate
mutants wherein the transposon reporter was specifically up-regulated during co-culture with
malignant cells.

Verification and characterization of Salmonella gene activation events in the
context of tumor cell co-culture
Following the primary screen, we utilized inverse touchdown PCR to map the specific
location of each transposon in the Salmonella genome (15). Table 1 documents the site of
chromosomal integration for the transposon and candidate gene up-regulated in each isolate. All
genes were novel in that they have not been previously reported to be involved in Salmonellahost interactions, nor involved in Salmonella colonization of neoplasia. Interestingly, the
genomic insertion sites of the transposon in three of the clones inserted in a cluster in the
chromosomal sequence. Mapped to three different, but closely linked genes (STM1787,
STM1791 and STM1793, respectively), two are known hydrogenases, and all three genes are
likely co-regulated and involved in the same Salmonella function. Sequencing showed that in
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one high stringency hit, the transposon had inserted into adiY, a Salmonella gene known to be
involved in an acid tolerance response (16). The transposon in the fifth clone was identified to
have landed in yohJ, a putative membrane protein (17).
To validate cancer cell co-culture-specific gene activation events identified in the primary
screen, we first repeated the co-culture assay in quadruplicate in at least three independent
experiments for each clone. Figure 2A shows the data from one representative experiment for
clones verified by this assay. Again, all five clones showed statistically significant enhancement
of bioluminescence in the presence of tumor cells, with a trend toward greater gene up-regulation
when co-cultured with B16F10 melanoma cells. Then, to further characterize tumor cell-induced
response of Salmonella, we utilized the tumor cells in a dose-response assay (Figures 2B, C).
Additionally, to verify that reporter activation seen in the Salmonella reporter-trap clones was
not an effect of differing substrate permeability due to mutations in bacterial genes, bacteria were
generated that contained the original chromosomal luxAB insertion as well as a plasmid
constitutively expressing luxCDE, the biosynthetic genes for the long-chain aldehyde that acts as
the optical substrate of the bacterial luciferase operon. Therefore, for this assay, it was not
necessary to add decanal to the media. Identical inoculations of bacteria showed greater upregulation of the reporter when exposed to greater numbers of tumor cells in co-culture
conditions, indicating that the stimuli from tumor cells instigated a graded response from the
bacteria. Because expression of the lux operon genes fully complemented the use of exogenous
decanal in the system, the data confirmed that the effect was not an artifact of exogenous decanal
permeability in the primary screen.
Finally, to verify that the reporters in fact reflected mRNA transcriptional regulation in
wild-type Salmonella during co-culture with tumor cells, we utilized semi-quantitative PCR.
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Following a three-hour co-culture of wild-type (SB3001A1) bacteria with B16F10 cells or in
tissue culture media alone, isolated RNA was reverse transcribed to cDNA. Semi-quantitative
PCR of cDNA showed that co-culture with B16F10 melanoma cells enhanced the intensity of
target gene transcripts, but not control ribosomal RNA transcripts (rrsH) (Figure 2D). The effect
was generalizable, as co-culture with HeLa tumor cells produced similar results (Figure 2D).
Notably, of the genes identified in this screen, at least one, adiY, has previously been
reported to be up-regulated in acidic pH conditions (16). One characteristic of tumor
microenvironments in vivo is an abnormally acidic pH (18). In fact, due to the Warburg effect,
cancer cells are constitutively glycolytic, even in high oxygen conditions, releasing lactic acid
and thereby creating a particularly acidic tumor microenvironment (19). For these reasons, the
Salmonella transposon insertion mutants were further investigated for reporter signal activation
in acidic conditions. Figure 3A shows that reporter signals increased in acidic pH media
compared to neutral media. Each of the clones up-regulated the reporter gene at pH 6.0
compared to the physiological pH of normal body tissue (pH 7.5), suggesting that the stimulus
Salmonella responded to in the context of neoplastic cells was microenvironment acidification.
To determine whether the activated genes were required for localization to tumors or
required for colonization and growth within tumors in vivo, Salmonella strains null for genes
identified in the screen were constructed. Selected genes were deleted using a lambda red
recombinase insertional deletion strategy, which inserted a chloramphenicol resistance cassette
into the targeted genes. The deletion mutants were created from a parental Salmonella strain
(luxCDABE msbB-) containing a chromosomally-integrated and constitutively-expressed
bacterial luciferase operon for imaging bacterial localtization in vivo in real time. The strain also
contained a msbB gene deletion, which causes a less immunogenic LPS structure and minimizes
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septic shock effects when the strain is administered intravenously (20). Based on the analysis
that the identified STM1787, STM1791 and STM1793 genes were contained in a single operon,
we targeted a large region of this operon for deletion in a single mutant strain, 1789-1793-. The
gene adiY also appeared to be a part of a larger operon of co-regulated genes and was therefore
targeted along with the adjacent genes adi and yjdE. The gene yohJ was targeted individually. In
a B16F10 melanoma tumor xenograft model, all bacterial strains were injected via mouse tail
vein and deletion mutants compared to the parental strain for localization to and persistence
within the tumor using bioluminescence imaging (Supplementary Figure 1). All mutant strains
and the parent strain were capable of tumor localization and persistence, indicating that although
the identified genes were activated by tumor cell co-culture in vitro, they were not essential for
bacterial colonization of the tumor. The experiment was also performed in an HCT116 colon
carcinoma xenograft model with similar results. Supplementary Table 1 summarizes the
numbers of mice with colonized tumors on or before day 10 in each experiment. Additionally, in
pilot competitive infection studies, there was no significant difference between the STM17891793 mutant and the parental Salmonella strain (luxCDABE msbB-) in tumor colonization
(CFU/ml; data not shown).

Specificity and reversibility of the Salmonella STM1787 promoter in vivo
We next sought to demonstrate the specificity of the STM1787 promoter activation in the
tumor microenvironment in vivo. We chose this promoter because it displayed the highest acidic
pH induction in vitro (Figure 2A). Here, we used the constitutively bioluminescent Salmonella
strain Tn:27.8+pluxCDE or the conditionally bioluminescent strain Tn:1787+pluxCDE, each of
which constitutively express plasmid-encoded luxCDE, but the latter strain will only
bioluminesce upon activation of the chromosomally-encoded luxAB reporter. In a B16F10
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melanoma tumor xenograft model, bacteria were injected via mouse tail vein or intratumorally
and allowed two days to localize and adapt to tumors in vivo. Tumors were then excised,
incubated in solutions of various pH values and imaged periodically for six hours. Initially, all
tumors showed bioluminescent bacteria ex vivo. Over time, constitutive Tn:27.8 Salmonella
showed a gradual increase in signal consistent with bacterial growth in the tumor explants. This
behavior was also observed in the Tn:1787 Salmonella-infected tumor explants incubated in low
pH media. By contrast, when the Tn:1787 Salmonella-infected tumor explants were maintained
in basic media conditions throughout, the signal initially increased, but then plateaued around 4
hours and decreased in comparison to the constitutively bioluminescent Tn:27.8 strain (Figure
3B,C). This finding suggested that bacterial gene expression was initially engaged by the low pH
conditions of the in vivo tumor microenvironment, but after exposure to a higher pH environment
ex vivo, the promoter driving the reporter was repressed and signal declined. Further, this ex vivo
effect was reversible. When the medium on the Tn:1787 Salmonella-infected tumor explant was
changed from pH 6.0 to pH 7.5, the bioluminescent signal decreased. Conversely, when the
media was changed from pH 7.5 to pH 6.0, the signal increased (Figure 3B, C). These effects
were not seen with the constitutive Tn:27.8 Salmonella-infected tumor explants, and provided
further evidence in support of the specificity of the trapped Salmonella promoter in the Tn:1787
transposon mutant for the tumor microenvironment.
Because the identified promoters were highly activated in the tumor microenvironment ex
vivo, utilization of these promoters provided a unique opportunity to design tumor-targeting
bacterial vectors subject to multiple levels of controlled specificity in vivo. Thus, we sought to
determine if the acidic pH of the tumor microenvironment could be exploited to specifically
activate a target transgene during tumor localization. As proof of principle, we constructed
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Salmonella reporter strains expressing plasmids encoding the bacterial luciferase operon driven
by either constitutive promoters or an inducible promoter to demonstrate tumor-mediated
transgene activation in vivo. The plasmids pMAAC001 and pLux both encoded constitutivelyexpressed luciferase operons, while the pPROMOTERLux plasmid was engineered to contain the
luciferase operon driven by the Salmonella candidate promoter (STM1787) comprising 500 base
pairs upstream of the putative transcription start site of tumor-activated genes STM1787,
STM1793 and STM1791 (which we will now refer to as the STM1787 promoter). Bacteria
expressing these plasmids were identically injected into mice bearing HCT116 tumor xenografts
on each flank (Figure 4). We chose to utilize intratumoral injection to directly compare reporter
gene activation from two different bacterial strains, one inducible and the other constitutive, over
time in the same mouse. Although reporter signals from pPROMOTERLux-expressing bacteria
were low immediately after injection into the tumor, the bacteria quickly induced a 90-fold
enhanced expression of the reporter after an 8 hr exposure to the tumor microenvironment
(Figure 4A). Concurrently, bacteria constitutively expressing pLux- or pMAAC001-luciferase
showed <20-fold or no reporter activation, respectively, after exposure to the tumor
microenvironment (Figures 4A and 4B). These data directly demonstrated tumor-specific
induction of a transgene from the Salmonella STM1787 promoter in an in vivo system. Therefore,
the STM1787 promoter could be used as a platform to design tumor-targeting Salmonella strains
capable of specifically delivering a therapeutic gene or toxin to the site of a tumor in vivo.

Selective anti-tumor therapy in vivo
We utilized the cancer cell-activated STM1787 promoter to regulate the expression of
Shiga toxin 2 (Stx2), a toxic transgene of bacterial origin, in a wild type strain of S. typhimurium
(SB300A1) to selectively induce tumor cell death in vitro and in vivo. Stx2 is a secreted AB5
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holotoxin composed of a single N-glycosidase A subunit that is directed to target eukaryotic cell
membranes through interaction of the pentameric B subunits and the host receptor,
glycosphingolipid globotriaosylceramide (Gb3) (21). Once inside the host cell, the A subunit
cleaves the 28S RNA of the 60S ribosomal subunit, thereby inhibiting peptide elongation and
inducing apoptosis. Stx2B has been extensively studied for its tumor targeting potential as many
invasive tumors display high levels of Gb3 (22).
Using bioluminescence as a reporter of total tumor cell mass, we performed a co-culture
experiment with HeLaCMV-Fluc cells in vitro. First, plated HeLa cells were grown to confluency to
acidify the media and then co-cultured with strain SB300A1 transformed with P1787 (empty
vector) or P7187-Stx2. Both SB300A1 transformants were also grown in media alone. The
supernatant was then filtered from each of the groups and aliquoted onto separately plated
HeLaCMV-Fluc cells in increasing volumes: 1) +media+P1787; 2) +media+P1787-Stx2; 3)
+HeLa+P1787; and 4) +HeLa+P1787-Stx2. After 24 hours of treatment, major toxicity was only
observed in HeLaCMV-Fluc cells treated with the supernatant of +HeLa+P1787-Stx2 (Figure 5A); a
general concentration-response trend was observed (Figure 5B). Stx2 expression was verified
using mRNA PCR amplification (Figure 5B inset). No overt cytotoxicity was observed in
HeLaCMV-Fluc cells treated with supernatant from any of the other conditioned media groups.
Given the selective regulation and associated toxicity of P1787-Stx2 in vitro, we next
desired to demonstrate the tumor-targeting potential in vivo using established s.c. flank HeLaCMVFluc

xenograft tumors and bioluminescence imaging.

In two independent proof-of-principle

experiments, intratumoral injection of a single high-dose of SB300A1 transformed with P1787Stx2 resulted in an 80% mean reduction in initial viable tumor mass five days after treatment
(Figure 6A). Furthermore, when tumors were treated with a single low-dose of SB300A1
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transformed with P1787-Stx2, a robust anti-tumoral effect was observed after two weeks (Figure
6B). We also observed that treatment with P1787 resulted in tumor stasis, consistent with
previous reports that S. typhimurium alone can block tumor growth in vivo, while LB broth alone
showed no inhibitory effect (23). To verify tumor cell death independent of bioluminescence
signal, tumor H&E sections from the high-dose treatment were analyzed (Figure 6C). Sections
through LB-treated (control) tumors showed a broad rim of viable tumor cells with focal necrotic
regions centrally. In the P1787 tumors, a thin rim of viable tumor cells was present in most
areas, with fibroinflammatory reaction at the periphery of the mass. The central necrotic zone
was larger and contained more neutrophils than in the LB-treated tumors. In the P1787-Stx2treated tumors, viable tumor cells were difficult to find, and in most sections, only a central
necrotic zone surrounded by fibroinflammatory reaction was present. Note that mice treated with
high-dose P1787-Stx2 eventually succumbed to the combined bacterial and Stx2 toxin load.
However, mice receiving low-dose P1787-Stx2 were healthy for two weeks, at which point the
experiment was concluded, but each still displayed a significant reduction in tumor size
compared to P1787 alone (Figure 6B).

Discussion
Salmonella typhimurium bacteria are typically classified as human gastrointestinal
pathogens and a common cause of modern food-borne illness. However, another noted
characteristic of Salmonella is the capacity to colonize tumor tissue. In fact, in the 1800’s,
physicians began to intentionally use bacteria as tumor therapeutics, but due to significant
toxicity and lack of consistent, reliable results, these practices were abandoned. However,
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modern studies using attenuated strains and longitudinal imaging have demonstrated colonization
of tumors by Salmonella in real time and have sparked a renewed interest in this concept using
Salmonella (23, 24) as well as various other tumor-localizing microbes as an option for cancer
treatment (25-31). These observations along with the current intense focus on developing PAMP/
TLR-based anti-cancer immunotherapies offer unique opportunities for combinatorial strategies
in tumor targeting.
Both wild-type and genetically engineered Salmonella are capable of inducing tumor
regression in mouse cancer models (4), as was observed in our experiments (Figure 6). A
number of studies utilize bacteria as treatment vectors per se or as drug delivery vehicles by
exploiting their potentially low toxicity and high genetic tractability to maximize therapeutic
efficacy (5). In this regard, various attenuated Salmonella strains have been developed for use in
tumor-targeting studies, including specific amino acid auxotrophs and LPS mutants (20, 32).
However, the greatly reduced toxicity of Salmonella LPS mutants (msbB-) observed in swine
models has not been observed in mouse models (33, 34). In more than one instance, attenuated
Salmonella have even been used in a clinical trial to treat cancer in humans (35, 36). However,
trials so far show relatively low rates of tumor colonization in human hosts, which may be due to
excessive attenuation of the bacterial strains (5, 34). Indeed, one study indicates that induction of
TNFα by bacteria is necessary for optimal colonization of tumors (37). Nonetheless, few studies
have investigated the phenotypic and gene expression patterns of these tumor-targeting bacteria
following exposure to tumor cells.
In this study, we utilized an engineered transposon to interrogate the Salmonella genome
for genes activated during exposure to cancer cells. Toward this objective, we generated a library
of greater than 7,400 independent transposon insertions, which, assuming random integration,
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would predict genomic transposon insertion into each of Salmonella’s 4,620 genes at least once.
From this library, we identified five Salmonella genes specifically up-regulated during co-culture
with cancer cells: STM1787, STM1791, STM1793, adiY and yohJ. Following identification of
these tumor cell-activated genes, verification in secondary assays and confirmation in wild-type
Salmonella, we determined that the common stimulus for up-regulation of target gene expression
was acidic pH. In another study aimed at identifying Salmonella promoters involved in tumor
colonization in vivo, Salmonella genomic DNA was digested and ligated randomly upstream of a
GFP reporter. In this study, the major stimulus identified in reporter activation was hypoxia, but
no pH-regulated promoters were identified (38).

Another recent study performed a similar in

vivo screen utilizing a promoter-trap GFP based system and indentified a conserved ‘tumor
specific’ DNA motif (tusp) in the promoters of Salmonella genes specifically activated in a
tumor xenograft model (33). While pH and hypoxia are physiologically linked, the five genes
identified herein show no overlap with the promoters identified by Leschner et al. (33) nor
Arrach et al. (38). However, the STM1787 promoter located upstream of three of our own target
genes (STM1787, STM1791, and STM1793) did contain the conserved tusp motif identified by
Leschner et al. (tattttatataaa). The discrepancy in promoter identification may stem from the
different bacterial strains or strategies utilized for gene identification in the two studies.
Whereas Arrach et. al. utilized a plasmid-based overexpression system, the present study
identified genes by chromosomal integration of a transposon. Nonetheless, hydrogenase genes
are noted in some cases to be up-regulated in low oxygen conditions, indicating that hypoxia
may serve as a further stimulus for the pH-induced promoters identified in the present study (39).
However, in pilot studies with an incubation pouch system used for growing anaerobic bacteria,
we did not observe any significant changes in transposon reporter activity under hypoxic
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conditions (KF, unpublished data). While these data do not necessarily rule out oxygenindependence, pH appeared to be the dominant signal inducing responses in the promoters
identified by our bioluminescent transposon reporter-trap screen. It will also be of interest in
future studies to determine if in addition to hypoxia, pH is another regulator of Salmonella
promoters that contain the largely uncharacterized tusp motif.
In view of the usual pathophysiology of Salmonella, it is not surprising that Salmonella
strains have gained the ability to precisely regulate genes in response to different pH
environments. Salmonella encounter low pH conditions regularly during human infection, for
example, during transit through the stomach, and later during intracellular trafficking through the
phagosome (40, 41). Interestingly, the acidic pH of the tumor environment in vivo has long been
noted as an important microenvironmental condition when designing effective tumor treatments
(18, 42). Additionally, the low pH environment of the tumor inhibits host defense. Cytotoxic
immune cell activity and cytokine secretion has been shown to be impaired by a low
extracellular pH (43). In contrast, with a bacterial-driven tumor therapeutic, low pH may become
an exploitable advantage, by adding another level of selectivity to bacterial gene activation.
Indeed, the utility of a low pH-activated bacterial therapeutic will avoid toxicity to the liver and
spleen which are the other major off-target organ sites of bacterial colonization, but which
generally have a neutral pH (33). In this case, a bacterial-based system may succeed, while both
conventional therapeutics and host defenses fail.
When using bacteria as a vector for drug delivery studies, tumor-specific colonization
and subsequent expression is a major concern. The genes identified herein are highly expressed
in an acidic tumor environment, but are not required for bacterial tumor targeting (Supplemental
Figure 1). Therefore, the promoters regulating these genes and further dissection of the complex
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regulation of the tusp motif may generate ideal chromosomal insertion site candidates or
synthetic promoter systems for utilization in therapeutic gene, pro-drug or toxin delivery studies.
We have identified the STM1787 promoter as an ideal bacterial sequence capable of driving
tumor-specific expression of a transgene, and demonstrated this in vivo using bioluminescent
imaging. We further applied the STM1787 promoter to conditionally regulate the expression of
Stx2 in wildtype S. typhimurium in tumor targeting toxicity models in vitro and in vivo. In proofof-principle studies, we observed dramatic cancer cell death in a co-culture model in vitro and
dramatic tumor response over a relatively short time scale with a robust therapeutic effect in
vivo. Future pharmacokinetic studies with P1787-Stx2 will be required to optimize mode of
delivery, dose, and efficacy. In addition, it will be of interest to take advantage of the recent
discovery that manganese treatment protects the host against lethal levels of Shiga toxin (44).
Clearly, other relevant tumor toxins could be explored downstream of STM1787.
In summary, by adapting the STM1787 promoter in Salmonella to drive expression of an
appropriate therapeutic transgene, the resulting bacterial vector would provide two independent
mechanisms for specifically targeting tumors. First, Salmonella specifically localize to and
accumulate in primary tumors and metastases in vivo. Second, the STM1787 promoter is
preferentially activated in the acidic tumor microenvironment. The combined effect of these two
levels of specificity provides a potential option to design more successful PAMP/ TLR-based
immunotherapeutic bacterial systems in the future.
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Methods
Bacterial strains and culture conditions
The Salmonella typhimurium strains SB300A1 (14), SB300A1FL6 (luxCDABE) (45), luxAB and
AM3 (luxCDABE msbB-) were grown in LB broth with appropriate antibiotics. SB300A1FL6 is
modified by chromosomal integration of luxCDABE and is constitutively bioluminescent. The
luxAB strain consists of SB300A1FL6 with the integrated luxE gene disrupted. This strain does
not bioluminesce without addition of exogenous decanal substrate. The AM3 strain has the
SB300A1FL6 background, but also has an msbB gene disruption, giving it a less immunogenic
LPS structure. The Tn:27.8 strain, specifically identified from the screen as a non-inducible
mutant, phenocopies luxAB with constitutive bioluminescence that requires exogenous decanal.

Tissue culture cell lines and culture conditions
B16F10 murine melanoma and HeLa cells were obtained from ATCC and cultured according to
ATCC directions. HCT116 human colon carcinoma cells were a gift from Bert Vogelstein and
were cultured according to ATCC methods. Cell lines were not further authenticated.
Plasmids: The plasmid pMAAC001 contains the full bacterial luciferase operon luxCDABE
driven by a T7 promoter and an ampicillin resistance cassette. The plasmid pLuxCDE consists of
the pMAAC001 backbone amplified using the forward primer cccgggattggggaggttggtatgtaa and
the reverse primer cccgggtgaatgatttgatgagccaaa (XmaI sites underlined). This product was then
XmaI digested and re-ligated to exclude the majority of the luxA and luxB genes. pLux and
pPROMOTERLux plasmids were constructed by inserting the full bacterial luciferase operon
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between the KpnI and BamHI restriction sites in the vector pUC19. The pPROMOTERLux
plasmid additionally had a 500 base pair promoter region (STM1787) from the Salmonella
genome inserted upstream of the luciferase operon between the SacI and KpnI restriction enzyme
sites. The 500 base pair sequence was amplified from the Salmonella genome using the forward
primer aaagagctcacgccctctttcaaacagtc and the reverse primer aaaggtaccgcttgataaaaggtctcctcgt
(SacI and KpnI sites underlined). To construct the P1787-based vectors, 500bp of the
endogenous SB300A1 1787 promoter was cloned into the BglII and NdeI sites of pET3a
(Novagen) using the following primers: forward-gagagagaagatct gggacgccctctttcaaacagtctc,
reverse- ccttcctgcccatatgaacgcgtattttttctcctttttgcacc. This cloning strategy conserved the
endogenous 1787 Shine-Dalgarno sequence and removed the T7 promoter and synthetic RBS of
pET3a. The P1787-Stx2A/B vector was constructed by inserting the Stx2A/B operon downstream
of the 1787 promoter using NdeI and BamHI with the following primers: forwardgagagagacatatgaagtgtatattatttaaatgggtactgtgcctgttactgggtttttcttcggtatcc, reverseccttccttccggatccttatcaatggtgatggtgatggtgg.

Construction of a Salmonella typhimurium reporter-trap library
Salmonella strain SB300A1 was used to construct a bacterial library comprising approximately
7,400 clones of unique chromosomal integrations of our reporter transposon (14). The custom
Tn5-based transposon was designed with the EZ-Tn5 system (Epicentre, Madison, WI) using the
pMOD4 transposon construction vector. A kanamycin-resistance cassette and promoter from EZTn5<KAN-2> was amplified using the forward primer acgacaaagcttggacgcgatggatatgttct and the
reverse primer agcttttctagaggtggaccagttggtgattt (HindIII and XbaI restriction sites underlined)
and inserted into the HindIII and XbaI restriction sites of pMOD4. The luciferase enzyme genes
luxAB

from

Photorhabdus

luminescens

were
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amplified

with

the

forward

primer

acagtcgaattccgccgaatgagaattgagat and the reverse primer aagctgggtacctgttggctgctttcactcac
(EcoRI and KpnI sites underlined) and inserted between the EcoRI and KpnI sites in pMOD4
(45). The plasmid contained an R6Kγ origin of replication and therefore was amplified in E. coli
DH5α λpir, purified, digested with PvuII, and the transposon fragment recovered by gel
purification. The purified transposon was combined with transposase (Epicentre). After bench
top incubation for 30 minutes, followed by 48 hours at 4°C, the transposon DNA was
electroporated into bacteria as per the vendor’s instructions. Bacteria were plated on LB
kanamycin plates to select for transformants containing the chromosomally-integrated
transposon. Each clone was expanded and stored in 60% glycerol in 96-well plates at -80°C.

Screening the library
To screen for gene activation events occurring in the context of malignant cells, Salmonella
library clones were cultured under three different conditions: co-culture with B16F10 mouse
melanoma cells, co-culture with HCT116 human colon carcinoma cells and culture in media
alone. Each of the two tumor cell lines were seeded into 96-well white plates at approximately
70-80% confluency in DMEM with 10% FBS. In the plate containing media alone, each well
contained 100 μl of DMEM with 10% FBS only. Plates were incubated overnight to allow tumor
cell adhesion to the 96-well white plates. Independently, bacterial clones were grown overnight
in LB broth with kanamycin in 96-well plates and subcultured the following day 1:10 into LB
broth. Five to six hours after subculturing, 30 μl of bacterial culture were added to three replicate
plates, each corresponding to a separate culture condition. Bacteria were allowed to co-incubate
with the malignant cells or media alone for 2 hours. Subsequently, bacteria were imaged by
adding 30 μl of decanal solution, waiting 10 minutes, and imaging with an IVIS 100 imaging
system (Caliper; acquisition time, 60 sec; binning, 4; filter, < 510; f stop, 1; FOV, 23 cm) (46).
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Because white plates were used to maximize signal intensity, images were aquired utilizing a
<510 filter to reduce phosphorescence from the plates. Three control wells were included on
every plate comprising:

luxCDABE Salmonella (SB300A1FL6), which contain the full

luciferase operon inserted into the chromosome; luxAB strain, which contains the luciferase
enzyme genes only and therefore requires addition of exogenous substrate to image reporter
activity in the assay; and a blank well, which contained media, but was not inoculated with
bacteria, to serve as a control for background luminescence. Imaged plates were analyzed with
Living Image (Caliper) and Igor (Wavemetric) analysis software packages as described (47).
Data were normalized by dividing the photon flux of experimental wells by media alone wells
and presented as the log2 of the normalized photon flux data.

Identification of hits
Library screening data representing photon flux from each well of a library plate were analyzed
with Image J software (48). To identify statistically significant hits from the primary screens, we
utilized a set of statistical requirements. First, a threshold was set to identify active clones.
Clones that did not produce photon signals greater than three standard deviations above the
signal in the un-inoculated, media alone wells were not further analyzed. A quartile method of
statistical analysis was then applied to the remaining clonal data (49). For quartile analysis,
plates of clones were grouped by assay date into sets for data analysis. For each set, we
normalized data by calculating the log2 of the fold-change of photon flux signal between the
condition of interest (co-culture with B16F10 or HCT116 cells) and media alone. From this data,
we calculated the median (Q2), first (Q1), and third (Q3) quartile values. The boundary for hit
selection was calculated as Q3 + c(ICQ), where ICQ = Q3-Q1 and c = 1.7239, corresponding to
a high stringency targeted error rate of α = 0.0027 (49).
141

Verification of primary screen hits
To verify hits identified by the primary screen, clones were tested again in a similar manner, in
quadruplicate. The assay followed the same steps as those in the primary screen, except each
clone was tested in 4 wells under each of three conditions across a 12-well row in a black 96well plate. Imaging was done with an IVIS 100 imaging system (acquisition time, 60 sec;
binning, 4; filter, open; f stop, 1; FOV, 23 cm).

Identification of transposon insertion site
To map sites of transposon integration in the chromosome of clones of interest, an inverse
touchdown PCR strategy was used (15). Genomic DNA was isolated from bacteria using
DNAzol (Molecular Research Center, Cincinatti, Ohio). PCR was performed using bacterial
chromosomal DNA, 20 pmols of a primer specific to the 5’ end of the transposon
(atggctcataacaccccttg), and 100 pmols of a degenerate primer (cggaatccggatngayksnggntc).
Reactions were initiated with a 95°C preparation step for 5 minutes, followed by 25 cycles
comprising denaturation at 95°C for 45 seconds, annealing at various temperatures for 45
seconds and extension at 72°C for 2 minutes. The annealing temperature started at 60°C and
decreased 0.5°C per cycle for the subsequent 24 cycles. Then PCR proceeded with 25 cycles of
95°C for 45 seconds, 50°C for 45 seconds and 72°C for 2 minutes. PCR reaction products were
fractionated on a 1% agarose gel, and the most prominent bands in each lane were excised and
gel purified (Qiagen kit). For some reactions, PCR products were purified (Qiagen) and the
resulting purified PCR product was used as a template for a second round of PCR using a
different transposon-specific primer (aacatcagagattttgagacacc) before gel purification of
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products. The cycling conditions and degenerate primer used in the second round of PCR were
the same as round one.

Semi-quantitative RTPCR
Salmonella strains SB300A1, P1787 or P1787 transformed SB300A1 were subcultured from a
stationary phase culture 1:10 and grown for 6 hours. Bacteria were then diluted 1:20 and 30 μl
added to 96-well plates containing tissue culture media alone, B16F10 melanoma cells or HeLa
cells, seeded 24 hours previously at 100,000 cells/well and 50,000 cells/ well, respectively. After
three and a half hours of co-culture, extracellular media containing bacteria was removed from
the 96-well plates and triplicates pooled. Media were centrifuged to pellet bacteria and pellets
were frozen at -80°C. After thawing, pellets were resuspended in 200 μl water with 5 mg/ml
lysozyme and incubated at room temperature for 5 minutes. Then, 700 μl of RLT buffer was
added and bacterial RNA was purified using the Qiagen RNeasy kit (Qiagen Inc, Valencia, CA).
Samples were then treated with DNase I at room temperature for 15 minutes, after which EDTA
was added and samples were incubated for 10 minutes at 65°C to inactivate the DNase. Samples
were then ethanol precipitated and resuspended in 30 μl water. For reverse transcriptase PCR, 1
μg of total RNA was used as a template and reverse transcribed using Superscript II Reverse
Transcriptase and 300 ng random primers as per the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). Following RTPCR, samples were treated with RNase H for 25 minutes at 37°C.
To perform semi-quantitative PCR, samples were amplified using primers specific to each gene
target

or

to

ribosomal

ggttggtcataagcctgtcg),

RNA:

STM1787

STM1791

(forward:

(forward:

tcggtagatcgcatgatgtc,

acacgggaacatccagattc,

reverse:
reverse:

cggcaaaggacaaatctcat), STM1793(forward: ttcggcaacctgtttttagg, reverse: acgcctccttgcataatcac),
adiY

(forward:

ccttattgaccgccaactgt,

reverse:
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gtggtcaagaaagcgggata),

yohJ

(forward:

caggcatttttcttgcatca, reverse: cgccatataacgaatcagca), rrsH (forward: cagccacactggaactgaga,
reverse:

gttagccggtgcttcttctg),

ggccacagtccccagtatcgct)

and

Stx2A

(forward:

atgacgccgggagacgtgga,

reverse:

Stx2B

(forward:

gcaatggcggcggattgtgc,

reverse:

acaatccgccgccattgcat). PCR cycling conditions were: 95°C for 5 minutes, 30 cycles (or 20 cycles
for rrsH reactions) of denaturation at 95°C for 45 seconds, annealing at 50°C for 45 seconds and
extension at 72°C for 1 minute. PCR products were fractionated on a 1% agarose gel.

Construction of deletion mutants
Mutant strains deficient for the identified target genes were constructed in Salmonella strain
luxCDABE msbB- (AM3), which contains a constitutively active, chromosomally-encoded
bacterial luciferase operon as well as a mutation in msbB to create a less immunogenic LPS
structure. Mutants were constructed using a lambda red recombinase strategy (50). First, primers
were designed to amplify the chloramphenicol-resistance cassette in pKD3 with tails flanking the
targeted locus of the Salmonella genome to be deleted. Primer sequences specifically targetting
the

genome

for

each

mutant

were

used

(adi

forward

targetting

primer:

atgaaagtattaattgttgaaagtgagtttctgcatcaggacacctgggtgtgtaggctggag-ctgcttc, adi reverse targetting
primer:

atcctgtttaaccggcgcatccagcggatacgggtttttgtgaatgc-ggtcatatgaatatcctccttag; yohJ forward

targetting primer:

agtaagtcactgaatattatctg-gcaatatatacgcgcttgtgtaggctggagctgcttc, yohJ reverse

targetting primer: ttttttcgttcc-cttctgcccaaccactttacgctcaccgcatatgaatatcctccttag; STM1789-1793
forward

targetting

primer: atgaatgcgcaacgcgtagtggtgatggggttaggaaaccgtgtaggctggagctgcttc,

STM1789-1793 reverse targetting primer: ctaataaagttcatgatcgttgcggcggagggtccccaggcatatgaatatcctccttag). PCR fragments were then electroporated into AM3 bacteria expressing plasmidencoded red recombinase. Following electroporation, growth on chloramphenicol plates at 37°C
selected for strains that had lost the temperature-sensitive recombinase plasmid and inserted the
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chloramphenicol-resistance cassette into the targeted genomic loci. Deletion of the genes was
confirmed by PCR.

Dose-response to tumor cells
To test the dose-response of hits from the screen to tumor cell co-culture, the assay was
performed as described, except that either B16F10 or HCT116 cells were plated at 1x105; 2 x105;
or 3 x105 cells per well 24 hours before co-culture with bacteria. Stationary phase bacteria were
diluted 1:50 and incubated for 6 hours before identical aliquots were allowed to co-culture with
the malignant cells. Growth curves performed for each mutant strain at different pH values
showed no significant differences. Imaging was done with an IVIS 100 imaging system
(acquisition time, 10 sec; binning, 8; filter, open; f stop, 1; FOV, 20 cm). Imaged plates were
analyzed with Living Image (Caliper) and Igor (Wavemetrics) analysis software packages as
described (47).

Assaying promoter activation in different pH media
Stationary phase bacteria were subcultured 1:100 into LB broth. Five to six hrs after
subculturing, 10 μl of bacterial culture were added to 190 μl pre-warmed HEPES-buffered media
in black 96-well plates adjusted to different pH values, and allowed to incubate for three and a
half hours. Bacteria were then imaged with an IVIS 100 imaging system (acquisition time, 60
sec; binning, 8; filter, open; f stop, 1; FOV, 20 cm).

Mouse imaging studies
To generate tumor xenografts, 6-week old nu/nu mice (Taconic) were injected subcutaneously in
the right flank with 1 x106 B16F10 cells or 2.5 x106 HCT116 cells in 100 μl PBS. Tumors were
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allowed to grow for two (B16F10) or three (HCT116) weeks before bacterial challenge.
Saturated cultures of strain AM3 and deletion mutant bacteria were subcultured 1:100 into LB
and grown for 3 hours. Bacteria were then diluted to 1 x106 bacteria/ ml (based on OD600
readings) and 100 μl were injected via tail vein. Mice were imaged as indicated using an IVIS
100 imaging system (acquisition time, 60 sec; binning, 8; filter, open; f stop, 1; FOV, 20 cm).
Photon flux data were calculated by utilizing user-determined regions of interest (ROIs) around
bioluminescent tumors with Living Image software.
For in vivo promoter inducibility experiments, 6-week old nu/nu mice (Taconic) were injected
subcutaneously in the right and left flanks with 1 x107 HCT116 cells in 100 μl PBS. Tumors
were allowed to grow for one week. Saturated cultures of Salmonella strain SB300A1 containing
plasmids pMAAC001, pPROMOTERLux, or pLux were subcultured 1:100 into LB and grown
for 3 hours. Twenty microliters of bacterial culture were injected intratumorally. Mice were
imaged as indicated using an IVIS 100 imaging system (acquisition time, 180 or 60 sec; binning,
8; filter, open; f stop, 1; FOV, 25 cm). Photon flux data were calculated by utilizing softwaredetermined regions of interest (ROIs) around bioluminescent tumors with Living Image
software.

Tumor ex vivo imaging
6-week old nu/nu mice (Taconic) were injected subcutaneously in the right flank with 1 x105
B16F10 cells and tumors allowed to grow for two and a half weeks. Saturated cultures of
bacteria were diluted and 5 x105 bacteria (based on OD600 readings) were injected intratumorally.
At 24 and 48 hours following bacterial injections, mice were sacrificed, and tumors excised and
dissected into 4 sections each. The bacterial-colonized tumor sections were incubated in
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HEPES/Tris-buffered media at the indicated pH values and imaged using an IVIS 100 imaging
system at the indicated times (acquisition time, 180 sec; binning, 8; filter, open; f stop, 1; FOV,
12 cm).

In vitro toxicity assays
Confluent HeLa cells or mock media alone (DMEM + 10% FBS) were inoculated at 1:100 with a
stationary culture of SB300A1 transformed with P1787 or P1787-Stx2A/B and cultured at 37 ⁰C
for 18 hours. The cultured media was then separately filtered through a 0.22 μm filter to remove
the bacteria and subsequently aliquoted at various volumes onto HeLaCMV-FLuc cells pre-plated in
a 96 well plate in quintuplicate. 24 hours later, bioluminescence of the conditioned mediatreated HeLaCMV-FLuc cells was imaged using an IVIS 100. Phase contrast microscopy (TMS-F,
Nikon) was used in parallel to qualitatively confirm loss of cell viability.

In vivo toxicity assays
6 week old male homozygous CrTac:NCr-Foxn1nu mice (Taconic) were subcutaneously injected
in the right flank with of 4.5 x 106 HeLaCMV-FLuc cells in 20 μL DMEM. When tumor volumes
reached approximately 100 mm2 (5 days later), mice were injected i.p. with 150mg/ kg of Dluciferin and 10 minutes later imaged using an IVIS 100. Immediately following imaging, mice
were injected intratumorly with LB broth, or SB300A1 transformed with P1787, or SB300A1
transformed with P1787-STx2A/B at either 2.5 x105 (low-dose) or 2 x 106 (high-dose) CFU/
injection. Mice (n= 9-14 in each group) were weighed and imaged for bioluminescence every
five days for 2 weeks. Viable tumor mass is presented as fold-initial photon flux (pre-treatment/
post-treatment).
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Histology
Tumors were excised and immediately frozen at -80°C. Frozen tumors were fixed in 10% neutral
buffered formalin for 24 hours. Prior to paraffin embedding, histology sectioning and H&E
staining, fixed tumors were washed with 30%, 50% and then 70% ethanol for 5 minutes each.
Statistics: Error bars represent the standard error of the linearly regressed data or the standard
error of the mean where noted.

148

Acknowledgements
The authors thank colleagues of the Molecular Imaging Center for helpful discussions and Reece
Goiffon for statistical assistance and David Haslam for the Stx2 plasmid. This study was
supported in part by a grant from the National Institutes of Health to the Molecular Imaging
Center at Washington University (P50 CA94056), NIH Training Grants T32 GM007067 for
stipend support to K.F. and T32 CA113275 for stipend support to B.K., and The Siteman Cancer
Center supported in part by a NCI Cancer Center Support Grant (P30 CA91842).

149

B.3 References
1.

Ellis, M., Ding, L., Shen, D., Luo, J., Suman, V., Wallis, J., et al. Whole genome
sequencing to characterise breast cancer response to aromatase inhibition Nature, 2012,
in press.

2.

Cairns, R., Papandreou, I., and Denko, N. Overcoming physiologic barriers to cancer
treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res, 4: 6170, 2006.

3.

Hanahan, D. and Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 144:
646-674, 2011.

4.

Gardlik, R., Behuliak, M., Palffy, R., Celec, P., and Li, C. J. Gene therapy for cancer:
bacteria-mediated anti-angiogenesis therapy. Gene Ther, 18: 425-431, 2011.
Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer, 10:
785-794, 2010.

5.

6.

Forbes, N. S., Munn, L. L., Fukumura, D., and Jain, R. K. Sparse initial entrapment of
systemically injected Salmonella typhimurium leads to heterogeneous accumulation
within tumors. Cancer Res, 63: 5188-5193, 2003.

7.

Zhao, M., Yang, M., Li, X. M., Jiang, P., Baranov, E., Li, S., et al. Tumor-targeting
bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella
typhimurium. Proc Natl Acad Sci U S A, 102: 755-760, 2005.

8.

Ganai, S., Arenas, R. B., Sauer, J. P., Bentley, B., and Forbes, N. S. In tumors Salmonella
migrate away from vasculature toward the transition zone and induce apoptosis. Cancer
Gene Ther, 18: 457-466, 2011.

9.

Kasinskas, R. W. and Forbes, N. S. Salmonella typhimurium lacking ribose
chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res, 67:
3201-3209, 2007.

10.

Martinon, F., Mayor, A., and Tschopp, J. The inflammasomes: guardians of the body.
Annu Rev Immunol, 27: 229-265, 2009.

11.

Garaude, J., Kent, A., van Rooijen, N., and Blander, J. M. Simultaneous targeting of tolland nod-like receptors induces effective tumor-specific immune responses. Sci Transl
Med, 4: 120ra116, 2012.

12.

O'Neill, L. A. and Bowie, A. G. The family of five: TIR-domain-containing adaptors in
Toll-like receptor signalling. Nat Rev Immunol, 7: 353-364, 2007.

13.

Pawelek, J. M., Low, K. B., and Bermudes, D. Bacteria as tumour-targeting vectors.
Lancet Oncol, 4: 548-556, 2003.
150

14.

McKinney, J., Guerrier-Takada, C., Galan, J., and Altman, S. Tightly regulated gene
expression system in Salmonella enterica serovar Typhimurium. J Bacteriol, 184: 60566059, 2002.

15.

Levano-Garcia, J., Verjovski-Almeida, S., and da Silva, A. C. Mapping transposon
insertion sites by touchdown PCR and hybrid degenerate primers. Biotechniques, 38:
225-229, 2005.

16.

Kieboom, J. and Abee, T. Arginine-dependent acid resistance in Salmonella enterica
serovar Typhimurium. J Bacteriol, 188: 5650-5653, 2006.

17.
18.

The universal protein resource (UniProt). Nucleic Acids Res, 36: D190-195, 2008.
Tannock, I. F. and Rotin, D. Acid pH in tumors and its potential for therapeutic
exploitation. Cancer Res, 49: 4373-4384, 1989.

19.

Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. Understanding the Warburg
effect: the metabolic requirements of cell proliferation. Science, 324: 1029-1033, 2009.

20.

Low, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, et al. Lipid A mutant
Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in
vivo. Nat Biotechnol, 17: 37-41, 1999.

21.

O'Loughlin, E. V. and Robins-Browne, R. M. Effect of Shiga toxin and Shiga-like toxins
on eukaryotic cells. Microbes Infect, 3: 493-507, 2001.

22.

Engedal, N., Skotland, T., Torgersen, M. L., and Sandvig, K. Shiga toxin and its use in
targeted cancer therapy and imaging. Microb Biotechnol, 4: 32-46, 2011.

23.

Pawelek, J. M., Low, K. B., and Bermudes, D. Tumor-targeted Salmonella as a novel
anticancer vector. Cancer Res, 57: 4537-4544, 1997.

24.

Yu, Y. A., Shabahang, S., Timiryasova, T. M., Zhang, Q., Beltz, R., Gentschev, I., et al.
Visualization of tumors and metastases in live animals with bacteria and vaccinia virus
encoding light-emitting proteins. Nat Biotechnol, 22: 313-320, 2004.

25.

Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., and Vogelstein, B.
Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl
Acad Sci U S A, 98: 15155-15160, 2001.

26.

Dang, L. H., Bettegowda, C., Agrawal, N., Cheong, I., Huso, D., Frost, P., et al.
Targeting vascular and avascular compartments of tumors with C. novyi-NT and antimicrotubule agents. Cancer Biol Ther, 3: 326-337, 2004.

27.

Weibel, S., Stritzker, J., Eck, M., Goebel, W., and Szalay, A. A. Colonization of
experimental murine breast tumours by Escherichia coli K-12 significantly alters the
tumour microenvironment. Cell Microbiol, 10: 1235-1248, 2008.
151

28.

Stritzker, J., Weibel, S., Hill, P. J., Oelschlaeger, T. A., Goebel, W., and Szalay, A. A.
Tumor-specific colonization, tissue distribution, and gene induction by probiotic
Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol, 297: 151-162, 2007.

29.

Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J. F., Drake, C. G., Hipkiss, E. L.,
et al. Bacteriolytic therapy can generate a potent immune response against experimental
tumors. Proc Natl Acad Sci U S A, 101: 15172-15177, 2004.

30.

Bettegowda, C., Foss, C. A., Cheong, I., Wang, Y., Diaz, L., Agrawal, N., et al. Imaging
bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5iodouracil. Proc Natl Acad Sci U S A, 102: 1145-1150, 2005.

31.

Hajitou, A., Trepel, M., Lilley, C. E., Soghomonyan, S., Alauddin, M. M., Marini, F. C.,
3rd, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging.
Cell, 125: 385-398, 2006.

32.

Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., et al. Targeted therapy with a
Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast
tumors in nude mice. Cancer Res, 66: 7647-7652, 2006.

33.

Leschner, S., Deyneko, I. V., Lienenklaus, S., Wolf, K., Bloecker, H., Bumann, D., et al.
Identification of tumor-specific Salmonella Typhimurium promoters and their regulatory
logic. Nucleic Acids Res, 2011.

34.

Leschner, S. and Weiss, S. Salmonella-allies in the fight against cancer. J Mol Med
(Berl), 88: 763-773, 2010.

35.

Toso, J. F., Gill, V. J., Hwu, P., Marincola, F. M., Restifo, N. P., Schwartzentruber, D. J.,
et al. Phase I study of the intravenous administration of attenuated Salmonella
typhimurium to patients with metastatic melanoma. J Clin Oncol, 20: 142-152, 2002.

36.

Heimann, D. M. and Rosenberg, S. A. Continuous intravenous administration of live
genetically modified salmonella typhimurium in patients with metastatic melanoma. J
Immunother, 26: 179-180, 2003.

37.

Leschner, S., Westphal, K., Dietrich, N., Viegas, N., Jablonska, J., Lyszkiewicz, M., et al.
Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong
hemorrhage promoted by TNF-alpha. PLoS One, 4: e6692, 2009.

38.

Arrach, N., Zhao, M., Porwollik, S., Hoffman, R. M., and McClelland, M. Salmonella
promoters preferentially activated inside tumors. Cancer Res, 68: 4827-4832, 2008.

39.

Hayes, E. T., Wilks, J. C., Sanfilippo, P., Yohannes, E., Tate, D. P., Jones, B. D., et al.
Oxygen limitation modulates pH regulation of catabolism and hydrogenases, multidrug
transporters, and envelope composition in Escherichia coli K-12. BMC Microbiol, 6: 89,
2006.
152

40.

Ibarra, J. A. and Steele-Mortimer, O. Salmonella--the ultimate insider. Salmonella
virulence factors that modulate intracellular survival. Cell Microbiol, 11: 1579-1586,
2009.

41.

Foster, J. W. and Spector, M. P. How Salmonella survive against the odds. Annu Rev
Microbiol, 49: 145-174, 1995.

42.

Gerweck, L. E. and Seetharaman, K. Cellular pH gradient in tumor versus normal tissue:
potential exploitation for the treatment of cancer. Cancer Res, 56: 1194-1198, 1996.

43.

Muller, B., Fischer, B., and Kreutz, W. An acidic microenvironment impairs the
generation of non-major histocompatibility complex-restricted killer cells. Immunology,
99: 375-384, 2000.

44.

Mukhopadhyay, S. and Linstedt, A. D. Manganese blocks intracellular trafficking of
Shiga toxin and protects against Shiga toxicosis. Science, 335: 332-335, 2012.

45.

Flentie, K. N., Qi, M., Gammon, S. T., Razia, Y., Lui, F., Marpegan, L., et al. Stably
integrated luxCDABE for assessment of Salmonella invasion kinetics. Mol Imaging, 7:
222-233, 2008.

46.

Pfeifer, C. G., Marcus, S. L., Steele-Mortimer, O., Knodler, L. A., and Finlay, B. B.
Salmonella typhimurium virulence genes are induced upon bacterial invasion into
phagocytic and nonphagocytic cells. Infect Immun, 67: 5690-5698, 1999.

47.

Gross, S. and Piwnica-Worms, D. Real-time imaging of ligand-induced IKK activation in
intact cells and in living mice. Nat Methods, 2: 607-614, 2005.

48.

Rasband, W. ImageJ. 1.3.1_03 edition. Bethesda, Maryland: National Institutes of Health,
2005.

49.

Zhang, X. D., Yang, X. C., Chung, N., Gates, A., Stec, E., Kunapuli, P., et al. Robust
statistical methods for hit selection in RNA interference high-throughput screening
experiments. Pharmacogenomics, 7: 299-309, 2006.

50.

Datsenko, K. A. and Wanner, B. L. One-step inactivation of chromosomal genes in
Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A, 97: 6640-6645,
2000.

153

B.4 Figures
15

ME

luxA

luxB

Kan

ME

B16F10 Melanoma Cell Co-Culture

10

Salmonella

5
0

bkg sub
flat-fielded
cosmic

-10

44

3

x10
6

3
6

6

x10

B16F10
Melanoma

HCT116
2
1
Colon Carcinoma
1

Color Bar
Min = 3.803e+05
Max = 4.9008e+06

Click # KNF20070622165220
Fri, Jun 22, 2007 16:52:41
Bin:M (4), FOV23, f1, 1m
Filter: < 510nm
Click # KNF20070622165220
Click # KNF20070622165220 Camera: IVIS 1354, SI620SITE
Series:
Fri, Jun 22, 2007 16:52:41
Fri, Jun 22, 2007 16:52:41
Experiment: plate 47
Bin:M (4), FOV23, f1, 1m
Bin:M (4), FOV23, f1, 1m
Label:
Filter: < 510nm
Filter: < 510nm Camera: IVIS 1354, SI620SITE
Comment:
Camera: IVIS 1354, SI620SITE
Analysis Comment:

Series:
bkg plate
sub 47
Experiment:
Label: flat-fielded
cosmic
Comment:
Series:
Analysis Comment:
Experiment: plate 47
Label:
Comment:
Analysis Comment:

x10

33

2

22

Color Bar
Min = 3.803e+05
Max = 4.9008e+06

11

log Normalized Photon Flux

4

c
Series:
Experiment: plate 47
Label:
Comment:
Analysis Comment:

4

Color Bar
Min = 3.803e+05
Max = 4.9008e+06

bkg sub
flat-fielded
cosmic
bkg sub
flat-fielded
cosmic

Salmonella Clones

-15

15

HCT116 Colon Carcinoma Cell Co-Culture

10
5
0

Click # KNF20070622165220
Fri, Jun 22, 2007 16:52:41
Bin:M (4), FOV23, f1, 1m
Filter: < 510nm
Camera: IVIS 1354, 2
SI620SITE

Media Alone

Radiance (x106 photons/sec/cm2/sr)

1

7,400 Clones
2

6

3

4

x10

Color Bar
Min = 3.803e+05
Max = 4.9008e+06

-5

-5

-10

Salmonella Clones

Figure 1. Design and utilization of a high throughput screen to identify tumor cell-induced
gene activation events in Salmonella. (A) A schematic of the promoter trap system using Tn5based luxAB chromosomal integration. Expression of the promoterless luxAB reporter vector, and
resulting Salmonella bioluminescence, is dependent on “trapping” an active promoter upstream
of the chromosomal integration site. The transposon was randomly integrated into strain
SB300A1, and kanamycin-resistant colonies were selected and arrayed into 96-well plates for
library screening. Continued on next page
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Representative primary screening plates in triplicate show responses of Salmonella library strains
to three separate co-culture conditions: media alone (top), B16F10 melanoma cells (bottom left),
HCT116 colon carcinoma cells (bottom right). Hit 47.74, showing selective activation in coculture with cancer cells, is indicated by the black open arrowhead, while the signals in the upper
and central wells represent non-selective activation of clones. In each plate, wells H10, H11, and
H12 (red box) contain media and bacteria constitutively expressing luxCDABE, bacteria
constitutively expressing luxAB, and no bacteria, respectively, as controls. Primary library
screening data from Salmonella promoter trap clones co-cultured with B16F10 melanoma cells
(B) or HCT116 colon carcinoma cells (C). Data are reported as the log2 of the normalized signal
for each library clone, where normalized signal was the ratio of the signal in the condition of
interest to the signal in media alone.
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Figure 2. Verification of Salmonella gene activation events in the context of tumor cell coculture. (A) Salmonella reporter clones displaying gene activation signals during co-culture with
tumor cell lines (black bars, B16F10 cells; open bars, HCT116 cells). Salmonella strains luxAB
and Tn:27.8 contain chromosomal luxAB genes under constitutive promoter control; luxCDABE
Salmonella contain the full luciferase operon inserted into the chromosome; pMAAC001
constitutively expresses plasmid-encoded luxCDABE. (B, C) Salmonella reporter clones display
dose-responsive gene activation in co-culture with B16F10 and HCT116 cells. Bacteria were cocultured with 1x105, 2x105, or 3x105 B16F10 or HCT116 cells/well. Data were normalized as the
ratio of the signal in the condition of interest to signal in media alone. (Continued on next page)
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Error bars correspond to SEM. All p value calculations are between luxCDABE and the group
indicated by the symbol: * p ≤ 1x10-7; xp ≤ 0.06. (D) Semi-quantitative reverse transcriptase PCR
with wild-type SB300A1 bacteria verifies that genes identified by the reporter transposon screen
in Salmonella are activated during co-culture with B16F10 melanoma and HeLa tumor cells.
rrsH = ribosomal RNA.

157

16

*

14
12

*

10

8
6

*

4

*

2
0

luxCDABE

Tn:1787
+pluxCDE

Tn:1791
+pluxCDE

Tn:1793
+pluxCDE

Tn:adiY
+pluxCDE

100

Tn:yohJ
+pluxCDE

pH
6.0  7.5

4

Tn:1787
+ pluxCDE

33

10

6

Tn:1787
+ pluxCDE

x10

Time (Minutes)

6

300

3
2

2
1

x10

250

2
1

3
2

6

200

4
3

x10

150

11

3
2

6

100

22

x10

50

4
3

6

0.1

4
3

6

Tn:27.8
+ pluxCDE

4

x10

pH
7.5 6.0

1

4

6

44

x10

Tn:27.8
+ pluxCDE

Radiance (x106 photons/sec/cm2/sr)

Normalized Photon Flux (pH 6/pH7.5)

*

18

x10

Photon Flux (Fold-Initial, Fold-Constitutive)

20

2
1

1 Bar
Color
Min = 2.0987e
Max = 4.3273

Color Bar
Color Bar
1
1
Color BarMin = 2.0987e
Color Bar
Min = 2.0987e+05
bkg
Maxsub
= 4.3273
Min = 2.0987e+05Min = 2.0987e+05
Max = 4.3273e+06
flat-fielded
Max = 4.3273e+06Max = 4.3273e+06

cosmic

Click # KNF20101124141602_007
Click # KNF20101124190646_009
User: KF
Series:
Wed, Nov 24, 2010
Thu,17:16:2
Nov 25, 2010 23:6:46
Experiment: mice
Experiment:
27.8,Bar
21.4
Color Bar
Color
bkg sub
Min
= 2.0987e+05Min = 2.0987e+05
Em filter=Open Em filter=Open
Comment1:
BLabel:
bkg subA,
bkg
bkg
flat-fielded
Maxsub
= 4.3273e+06
Maxsub
= 4.3273e+06
Bin:HS (8), FOV12,
Bin:HS
f1, 3m
(8), FOV12, f1, 3m
Comment2:
Comment:
flat-fielded
flat-fielded
flat-fielded
cosmic
Camera: IVIS 13225,
Camera:
DW434
IVIS 13225, DW434
Time
Point:
seq
Analysis
Comment:
cosmic
cosmic
cosmic
Click
#
KNF20101124141602_007
User:
KF
Click # KNF20101124190646_009
Series:
Click # KNF20101124190646_009
Series:
Click # KNF20101124190646_009
Series:
Click # KNF20101124141602_007
User: KF
Wed,
Nov
24,
2010
17:16:2
Experiment:
mice
27.8,
21.4
Thu, Nov 25, 2010 23:6:46
Experiment:
2010 23:6:46
Thu,17:16:2
Nov 25,Em
2010
23:6:46 Thu, Nov 25,Experiment:
Experiment:
Wed, Nov 24, 2010
mice
27.8, 21.4 Comment1: A, Experiment:
filter=Open
B
Em filter=Open
Label:
bkg sub
bkgLabel:
sub
Em filter=Open
Em filter=Open Em filter=Open
Bin:HS
(8), FOV12, f1, 3m Comment1: A, BLabel:
Comment2:
Bin:HS (8), FOV12, f1, 3m
Comment:
Bin:HS
(8),
FOV12,
f1,
3m
Comment: flat-fielded
Bin:HS
(8), FOV12,
f1,IVIS
3m 13225, DW434
Comment: Time Point: flat-fielded
Bin:HS (8), FOV12,
f1, 3m
Comment2:
Camera:
seq
Camera: IVIS 13225, DW434
Analysis
Comment:
cosmic
cosmic
Camera: IVIS
13225,
DW434
Analysis Comment:
Camera:
IVIS 13225, DW434
Camera: IVIS 13225,
DW434
Time
Point:
seq Analysis Comment:
Click # KNF20101124190646_009
Series:
Click # KNF20101124141602_007
User: KF
Thu,17:16:2
Nov 25, 2010 23:6:46
Experiment:
Wed, Nov 24, 2010
Experiment: mice
27.8, 21.4
Em filter=Open Em filter=Open
Comment1: A, BLabel:
Bin:HS
(8), FOV12, f1, 3m
Comment:
Bin:HS (8), FOV12,
f1, 3m
Comment2:
Camera:
IVIS 13225, DW434
Camera: IVIS 13225,
DW434
Time Point: seq Analysis Comment:

Figure 3. Acidic pH specifically and reversibly stimulates the Tn:1787 trapped promoter.

(A) Bacteria were cultured in media of different pH values and reporter activation by Salmonella
library clones in low pH media (pH 6) were compared to reporter activation in normal pH (7.5).

Genes identified in the tumor cell co-culture screen were activated in the context of acidic pH
compared to pH 7.5. pMAAC001 and luxCDABE constitutively express plasmid-encoded and
chromosomally-encoded luxCDABE, respectively. Data were normalized as the ratio of the
signal in media pH 6.0 to signal in media pH 7.5. Error bars correspond to standard error.
(Continued on next page)
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The data show one representative experiment with 4 replicates per condition tested. All p-value
calculations are between luxCDABE and the group indicated by the asterisk, *p ≤ 2x10-14. (B)
Mice bearing B16F10 flank tumor xenografts were injected intratumorally with tumor-activated
(Tn:1787+pluxCDE) or constitutively bioluminescent (Tn:27.8+pluxCDE) Salmonella. The
excised tumors were imaged hourly and data are presented as the normalized signal at each time
point. The normalized signal represents the ratio of the mean of the fold-initial signal of two
Tn:1787+pluxCDE-colonized tumors to the mean of the fold-initial signal of two constitutive
Tn:27.8+pluxCDE-colonized tumors. The data presented are from a representative experiment;
the experiment was performed independently two times, each with two mice per bacterial
treatment group. (C) Representative ex vivo tumor imaging shows reversibility of the
bioluminescent signal in the tumor-activated Salmonella. Images on the left show Salmonellainfected tumor explants after 6 hours of incubation at the indicated pH (pH 6.0, top; pH 7.5,
bottom). Two hours later (8 hours total), media was removed and replaced with media of the
indicated pH (pH 7.5, top; pH 6.0, bottom). Images on the right show Salmonella-infected tumor
explants 4 hours after the pH of the media was changed.

159

120

3.0

2.5

Photon Flux (Fold-Initial)

1.5

6

1.0

2.0

x10

*

0.5

6

1.0

0.5

0.5

2.5

6

6

1.5

x10

x10

0.5

1.5

6

1.0

1.0

Color Bar
Min = 50000
Max = 3e+06

0.5

0.5

*

Color Bar
Color Bar
Min = 50000
Min = 50000
User:
KF
Max = 3e+06
Max
= 3e+06
Group:
Experiment: Mouse 6 and 7
Comment1: T=0
Comment2:

*

bkg sub
flat-fielded
cosmic

1

1.0

x10

60

2.0

6

80

1.5

2.0

3.0

x10

x10

1.5

pPROMOTERLux
Bar
pLux MinColor
= 50000
Max = 3e+06
pMAAC001

Click # KF20110728122052
Thu, Jul 28, 2011 12:20:52
Em filter=Open
Bin:M (8), FOV25, f1, 3m
Camera: IVIS 1354, SI620EEV

2.5
1.5

2.0

0.5

100

2

2.5

2.5

1.0

120

2.5

2.5

3.0
2.0

2.0

1.5

480
3.0

Radiance (x106 photons/sec/cm2/sr)

0

3

3.0

Time (Minutes)
3.0
240
360

bkg sub
flat-fielded
Color
Bar
cosmic
Min = 50000
Max = 3e+06

bkg sub
bkg sub
bkg sub
F20110728122052
User: KF
flat-fielded
flat-fielded
flat-fielded
28, 2011 12:20:52
Group:
cosmic
cosmic
Open
Experiment: Mouse 6 and 7
Click # KF20110728203429 cosmic
User: KF
Click # KF20110728162722
ClickT=0
# KF20110728184421
User: KF
User: KF
FOV25, f1, Click
3m # KF20110728143914
Comment1:
Group:
User: KF Fri, Jul 29, 2011 20:34:29
Thu, Jul 28, 2011
16:27:22
Thu, Jul 28, 2011 18:44:21
Group:
Group:
IVIS 1354, SI620EEV
Comment2:
Em filter=Open
Experiment: Mouse 6 7
Thu, Jul 28, 2011 14:39:14
Group:
Em filter=Open
Em filter=Open
Experiment: Mouse 6,7Experiment: Mouse 6, 7
(8),6,7
FOV25, f1, 1m
Comment1: T= 8 hours
Em filter=Open
Experiment:Bin:M
Mouse
Bin:M (8), FOV25, f1, 3m
Bin:M (8), FOV25, f1, 1m
Comment1: T= 4 hoursComment1: T= 6 hours
IVIS 1354, SI620EEV
Comment2:
Bin:M (8), FOV25, f1, 3m
Comment1:Camera:
T= 2 hous
Camera: IVIS 1354, SI620EEV
Camera: IVIS 1354, SI620EEV Comment2:
Comment2:
Camera: IVIS 1354, SI620EEV
Comment2:

Color Bar
Min = 50000
Max = 3e+06

bkg sub
flat-fielded
cosmic

40

*

20

*
0

120

240
360
Time (Minutes)

480

600

Figure 4. The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor
microenvironment. (A) A representative mouse with two HCT116 flank tumor xenografts. The
left tumor (black arrow) was injected with STM1787 pPROMOTERLux-expressing Salmonella,
while the right tumor (red arrow) was injected with constitutive pMAAC001-expressing
Salmonella, and the mouse imaged at the indicated times post-injection. (B) The mean photon
flux for each set of Salmonella-injected tumors, normalized to the initial signal in each tumor,
plotted as a function of time. Error bars represent SEM; pPROMOTERLux (n=6); pLux (n=3);
pMAAC001 (n=3), *p<0.025
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+ HeLa

+ P1787-Stx2

+ P1787

+ Media

Figure 5. P1787-driven Stx2 cytoxicity is selectively activated by the cancer cell
environment in vitro. (A) Representative brightfield microscopy of HeLaCMV-FLuc cells treated
with 4 different conditioned, filtered media for 24 hours (+media+P1787; +media+P1787-Stx2;
+HeLa+P1787; and +HeLa+P1787-Stx2). (Continued on next page)
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Note the dramatic membrane blebbing and apoptotic morphology of +HeLa+P1787-Stx2
conditioned media-treated cells. (B) Bioluminescence imaging of HeLaCMV-FLuc cells treated with
increasing amounts of 4 different conditioned, filtered media for 24 hours (bar groups, left to
right: 17%, 29%, 44% of total volume per well). *p<0.0005 compared to all other treatments.
Inset represents PCR amplification of Stx2A/B mRNA from P1787-Stx2 transformed SB300A1
co-cultured with HeLa cells.
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Figure 6. Enhanced anti-tumor response with P1787-Stx2 in vivo. (A) Viable cell mass of
HeLaCMV-FLuc tumors from mice treated with LB (n = 14), or high-dose SB300A1 transformed
with P1787 (n= 12) or P1787-Stx2 (n = 9) at five days post treatment. Results are combined from
two independent experiments and presented as fold-initial photon flux. Dotted line demarks lack
of fold-change in tumor bioluminescence. Error bars indicate standard error of the mean
***p<0.0002,**p<0.0003, *p<0.007). (B) Fold-initialized photon flux of HeLaCMV-FLuc tumors
from mice treated with low-dose SB300A1 transformed with P1787 (n= 7) or P1787-Stx2 (n = 7)
at 14 days post treatment. Error bars indicate standard error of the mean.*p <0.04. (C) H&E
staining of HeLaCMV-FLuc tumors from mice treated with LB (left), or high-dose SB300A1
transformed with P1787 (middle) or SB300A1 transformed with P1787-Stx2 (right) after five
days. Regions of tumor are denoted as tumor (T), fibroinflammatory reaction (I), and necrotic
zone (N). Scale bar, 500 µm.
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B.5 Table
Table 1. Transposon chromosomal insertion locations in Salmonella reporter mutants.
Strain Name

Transposon Insertion
Location

Function
(Putative) (17)

STM1787

Base pairs
Downstream of
Start Codon
1,189

Tn:1787
Tn:1791

STM1791

505

Hydrogenase

Tn:1793

STM1793

661

Tn:adiY

adiY

439

Tn:yohJ

yohJ

205

Cytochrome
oxidase
araC-like
transcriptional
activator;
argininedependent acid
tolerance
Hypothetical
membrane protein

164

Hydrogenase

B.6 Supplementary Figure

Supplemental Figure 1. Activated genes are not essential for Salmonella tumor localization.
Mice bearing B16F10 flank tumor xenografts were injected intravenously with constitutively
bioluminescent gene-deleted Salmonella. (A) Representative mice on day 10 post Salmonella
injection. (B) Bioluminescent photon flux of the four mice depicted in (A) as a function of time
following intravenous injection of bacteria.
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B.7 Supplementary Table

Supplementary Table I. Tumor localization of constitutively bioluminescent Salmonella
mutants.
Mutant

luxCDABE
STM1789-1793
adi
yohJ

Number of Mice with
Bioluminescent, Colonized
Tumors/Total Mice Injected
(HCT116 Tumors)
2/3
2/3
1/2
3/3
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Number of Mice with
Bioluminescent, Colonized
Tumors/Total Mice Injected
(B16F10 Tumors)
3/4
2/5
4/5
3/5

Totals

5/7
4/8
5/7
6/8

